<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Attention deficit hyperactivity disorder in adults: Treatment overview</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Attention deficit hyperactivity disorder in adults: Treatment overview</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Attention deficit hyperactivity disorder in adults: Treatment overview</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David Brent, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Oscar Bukstein, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mary V Solanto, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Murray B Stein, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Friedman, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 11, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1265042683"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Attention deficit hyperactivity disorder (ADHD), one of the most common neuropsychiatric disorders of childhood and adolescence, often persists into adulthood [<a href="#rid1">1</a>]. Studies have found that a majority of people diagnosed with ADHD in childhood continue to be significantly impaired as adults [<a href="#rid2">2,3</a>]. ADHD in adulthood is associated with significant impairment in occupational, academic, and social functioning.</p><p>Findings from clinical trials of medications for ADHD in adults echo many of the findings on effective medications in child/adolescent ADHD; however, these data are less extensive in adults compared with children, show greater variability in outcomes, and have generated less definitive information on medication efficacy and dosing [<a href="#rid1">1,2</a>].</p><p>This topic and two algorithms  (<a class="graphic graphic_algorithm graphicRef140086" href="/z/d/graphic/140086.html" rel="external">algorithm 1</a> and <a class="graphic graphic_algorithm graphicRef140088" href="/z/d/graphic/140088.html" rel="external">algorithm 2</a>) describe our management of ADHD in adults. The epidemiology, pathogenesis, clinical manifestations, assessment, diagnosis, and psychotherapy of adult ADHD are reviewed separately. Topics related to ADHD in children and adolescents are also reviewed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1232.html" rel="external">"Attention deficit hyperactivity disorder in adults: Epidemiology, clinical features, assessment, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/82780.html" rel="external">"Attention deficit hyperactivity disorder in adults: Psychotherapy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/623.html" rel="external">"Attention deficit hyperactivity disorder in children and adolescents: Overview of treatment and prognosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/602.html" rel="external">"Attention deficit hyperactivity disorder in children and adolescents: Epidemiology and pathogenesis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/624.html" rel="external">"Attention deficit hyperactivity disorder in children and adolescents: Clinical features and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/16927.html" rel="external">"Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/621.html" rel="external">"Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents"</a>.)</p><p></p><p class="headingAnchor" id="H894319274"><span class="h1">INITIAL TREATMENT</span></p><p class="headingAnchor" id="H4247047703"><span class="h2">Preference for combination medication and CBT</span><span class="headingEndMark"> — </span>We suggest first-line treatment with a combination of medication and cognitive-behavioral therapy (CBT) targeting executive dysfunction for most adults diagnosed with attention deficit hyperactivity disorder (ADHD). This is particularly true in individuals with severe executive dysfunction  (<a class="graphic graphic_algorithm graphicRef140086" href="/z/d/graphic/140086.html" rel="external">algorithm 1</a> and <a class="graphic graphic_algorithm graphicRef140088" href="/z/d/graphic/140088.html" rel="external">algorithm 2</a>). (See  <a class="medical medical_review" href="/z/d/html/82780.html" rel="external">"Attention deficit hyperactivity disorder in adults: Psychotherapy", section on 'Overview of management of ADHD in adults'</a>.)</p><p>Both stimulant medication [<a href="#rid4">4-7</a>] and CBT [<a href="#rid8">8-10</a>] have been reported to be effective treatments for ADHD in adults. However, there have been no clinical trials in adults directly comparing the efficacy of CBT and medication separately and in combination. Therefore, we rely on studies that conducted these comparisons separately. Medication clearly augmented the benefit of CBT in one randomized, controlled, adequately powered study [<a href="#rid11">11</a>]. Five studies have assessed the benefits of adding CBT to medication, with four studies reporting positive results [<a href="#rid12">12-15</a>] and one study reporting negative results [<a href="#rid16">16</a>]. However, none of these studies included a control for nonspecific effects of psychotherapy. Nevertheless, these results strongly suggest that the combination of stimulant medication and CBT is better than either treatment alone.</p><p>As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In a trial, 88 adults with ADHD were randomly assigned to 12 manualized group sessions either with (n = 42) or without (n = 46) stimulant medication [<a href="#rid11">11</a>]. At treatment end and three months, subjects in the treatment group (CBT and stimulant) showed greater improvement on observer-reported and self-reported scales than subjects in the CBT-only group. However, at six months, while both groups maintained gains, the difference in treatment effects lessened and were similar in overall improvement.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another trial, 95 adults with ADHD who were being treated with medication were randomly assigned to treatment as usual or 15 sessions of CBT [<a href="#rid12">12</a>]. At treatment end, subjects who received CBT experienced reduced ADHD symptoms (eg, Kiddie-Schedule for Affective Disorders and Schizophrenia [ADHD section], Clinical Global Impression scale, Barkley Current symptoms scale) as compared with the group receiving treatment as usual. This difference was maintained at three months. The effect size was noted to be modest (0.55) for a trial that did not control for the nonspecific effects of psychotherapy.</p><p></p><p>However, we modify the initial treatment for specific populations such as individuals with substance use disorder (SUD) or other co-occurring disorders. (See <a class="local">'Initial treatment for specific populations'</a> below.)</p><p>Additionally, for individuals with contraindications to medication, or in those who prefer not to take medication or engage in CBT, we use the patient preferred treatment as monotherapy. (See  <a class="medical medical_review" href="/z/d/html/82780.html" rel="external">"Attention deficit hyperactivity disorder in adults: Psychotherapy"</a>.)</p><p class="headingAnchor" id="H3370244087"><span class="h2">Stimulants as preferred pharmacologic treatment</span><span class="headingEndMark"> — </span>For most adults with ADHD, we suggest first-line pharmacologic treatment with a stimulant medication (eg, amphetamines or <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">methylphenidate</a>) rather than nonstimulant medications such as <a class="drug drug_general" data-topicid="8787" href="/z/d/drug information/8787.html" rel="external">atomoxetine</a> or antidepressants. An advantage of stimulant medication is that they have a clinical effect almost immediately after starting, while atomoxetine and the antidepressants have a delayed onset of full therapeutic action of up to four weeks, related both to the titration of the medication and the delay in the onset of action of the agent [<a href="#rid17">17</a>].</p><p>There are no direct comparisons between stimulant and nonstimulant medications in clinical trials. Meta-analyses have shown that effect sizes in short-term trials of adult ADHD are greater for stimulants compared with nonstimulant medications, including <a class="drug drug_general" data-topicid="8787" href="/z/d/drug information/8787.html" rel="external">atomoxetine</a> and atypical antidepressants (<a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a>, tricyclic antidepressants [TCAs], and <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">venlafaxine</a>) [<a href="#rid4">4-7</a>]. As an example, in a meta-analysis of 11 trials including 1991 adults with ADHD, pooled effect size for stimulants was somewhat greater versus placebo than for nonstimulant medications (Cohen’s d = 0.67 versus 0.59, respectively) [<a href="#rid5">5</a>].</p><p>A table on medications for adult ADHD describes their dosing, onset of action, and duration of effects  (<a class="graphic graphic_table graphicRef50379" href="/z/d/graphic/50379.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H852924817"><span class="h3">Choosing a stimulant</span><span class="headingEndMark"> — </span>Among the stimulant medications, our first choice is typically an <a class="drug drug_general" data-topicid="99959" href="/z/d/drug information/99959.html" rel="external">amphetamine</a> rather than <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">methylphenidate</a>. Within each of these groups there are various formulations without established superiority in efficacy. Our choice is based on the properties of the medication (eg, half-life, time to onset) and prescriber familiarity and preference.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Amphetamines</strong> – <a class="drug drug_general" data-topicid="99959" href="/z/d/drug information/99959.html" rel="external">Amphetamine</a> stimulants include <a class="drug drug_general" data-topicid="9341" href="/z/d/drug information/9341.html" rel="external">dextroamphetamine</a> and <a class="drug drug_general" data-topicid="10143" href="/z/d/drug information/10143.html" rel="external">lisdexamfetamine</a>, and can be short- or long-acting [<a href="#rid18">18</a>]. Amphetamine medications for ADHD are available in immediate- and extended-release formulations and have an onset of action of 20 to 60 minutes. The immediate-release formulation of <a class="drug drug_general" data-topicid="8723" href="/z/d/drug information/8723.html" rel="external">dextroamphetamine-amphetamine</a> has a duration of up to 6 hours [<a href="#rid19">19,20</a>]. Longer-acting formulations may last up to 10 to 12 hours [<a href="#rid19">19-22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Methylphenidate</strong><strong>/</strong><strong>dexmethylphenidate</strong> – <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">Methylphenidate</a> stimulants contain <a class="drug drug_general" data-topicid="8667" href="/z/d/drug information/8667.html" rel="external">dexmethylphenidate</a> or racemic mixtures of methylphenidate [<a href="#rid21">21,23,24</a>] and are either short-acting (3 to 5 hours), intermediate-acting (4 to 8 hours), or long-acting (8 to ≥12 hours). In addition to oral formulations, a methylphenidate patch is available and should be applied two hours before needed because of a delay in the onset of clinical effects.</p><p></p><p>While amphetamines and <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">methylphenidate</a> have long been considered comparably efficacious for adult ADHD, some data appear to show a benefit of amphetamines in reducing core symptoms of ADHD (eg, inattention, impulsivity, hyperactivity) compared with methylphenidate. In a network meta-analysis of 51 medication trials including 8131 adults with ADHD, after 12 weeks of treatment, individuals treated with amphetamines showed greater effect on clinician rating scales of overall ADHD symptoms than methylphenidate (standardized mean difference -0.29, 95% CI -0.54 to -0.05) [<a href="#rid7">7</a>]. However, amphetamines were associated with higher risk of treatment ending early as the result of adverse events. No differences in efficacy were seen between higher and lower doses of amphetamines.</p><p class="headingAnchor" id="H1970170594"><span class="h3">Long- versus short-acting stimulants</span><span class="headingEndMark"> — </span>Our choice of stimulant preparation is based on the patient’s preference, time to onset and length of desired effect, concern about misuse or diversion, cost, and availability of the medication. Some adults value the ability to target the short-acting drugs’ coverage to the desired part(s) of the day (eg, time in class or at work). Others prefer the simplicity of the longer-acting stimulant’s all-day or most-of-the-day coverage  (<a class="graphic graphic_table graphicRef50379" href="/z/d/graphic/50379.html" rel="external">table 1</a>).</p><p></p><p>Studies suggest that longer-acting stimulants may be less likely to be abused or diverted [<a href="#rid25">25-27</a>]. A lower abuse potential for long-acting compared with short-acting stimulants is based on studies demonstrating greater subjective responses and potential reinforcement for immediate-release stimulants compared with extended-release <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">methylphenidate</a> in healthy adults [<a href="#rid27">27</a>].</p><p>Despite pharmacologic and pharmacokinetic differences in stimulants used to treat adult ADHD, there does not appear to be differences in efficacy between short- and long-acting stimulants [<a href="#rid4">4,7</a>].</p><p class="headingAnchor" id="H996303115"><span class="h3">Pretreatment evaluation and contraindications</span><span class="headingEndMark"> — </span>Prior to initiating treatment with a stimulant in adults, we review their cardiovascular history including history of chest pain, palpitations, syncope, myocardial infarction, arrhythmia, valvular disease and their family history.</p><p>We measure blood pressure and pulse in all patients and obtain an electrocardiogram (ECG) in individuals with cardiac history or cardiac symptoms such as palpitations or chest pain. In individuals with a cardiac history, or when findings are outside of normal limits are seen, we consult with a cardiologist to determine whether the findings are sufficiently severe to avoid these medications [<a href="#rid28">28</a>].</p><p class="headingAnchor" id="H3575366424"><span class="h3">Dose and titration</span><span class="headingEndMark"> — </span>We typically begin treatment with a low dose of the chosen agent and increase weekly while monitoring for clinical response, duration of the effect during the day, and side effects  (<a class="graphic graphic_table graphicRef50379" href="/z/d/graphic/50379.html" rel="external">table 1</a>). (See <a class="local">'Monitoring'</a> below and <a class="local">'Defining response'</a> below.)</p><p>As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>For short-acting <a class="drug drug_general" data-topicid="8723" href="/z/d/drug information/8723.html" rel="external">dextroamphetamine-amphetamine</a>, we begin at 5 mg orally in the morning on the first day. If tolerated, we increase to 5 mg twice a day (approximately at breakfast and lunch; eg, four hours between doses) beginning on the day 2 to 7. We monitor for improvement (see <a class="local">'Monitoring'</a> below) in symptoms for one week. If adequate improvement is not seen, we increase by 5 mg at weekly intervals until clinical response is adequate, intolerable adverse effects limit further titration, or maximum total daily dose limit reached (60 mg).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For short-acting <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">methylphenidate</a>, we typically begin with 10 mg orally in the morning. If initial dose is tolerated, we increase to 10 mg at breakfast and lunch each day on day 2 to 7. Depending on response to medication, we increase by 10 mg at weekly intervals until clinical response is adequate, adverse effects limit further increases, or maximum daily dose is reached (60 mg).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For long-acting <a class="drug drug_general" data-topicid="8723" href="/z/d/drug information/8723.html" rel="external">dextroamphetamine-amphetamine</a> (mixed salts), we typically begin at 10 mg orally each morning. If there are no adverse effects after three or four days, we increase to 20 mg once per day in the morning. We increase by 10 mg at weekly (or longer) intervals until clinical response or a dose of 40 mg per day is reached. Doses above 40 mg per day are rarely necessary and require close monitoring.</p><p></p><p class="headingAnchor" id="H3373019764"><span class="h3">Benefits of stimulant treatment</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Symptomatic improvement </strong>– Stimulant medications have been shown to offer symptomatic improvement (particularly in attention and on-task behaviors) as well as improvement in daily functioning (vocational and interpersonal performance) in adults as compared with placebo [<a href="#rid5">5,7,18,29-32</a>].</p><p></p><p class="bulletIndent1">As examples, in a meta-analysis of trials, 1100 adults with ADHD were randomly assigned to receive stimulant medications or placebo for up to 12 weeks [<a href="#rid5">5</a>]. Participants who received stimulants experienced greater improvement in ADHD symptoms compared with placebo, with an estimated effect size in the medium to high range (Cohen’s d = 0.67). Another systematic review identified four trials in adults with ADHD that suggested potential improvement in investigator- or participant-reported symptoms with <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">methylphenidate</a> compared with placebo, although the evidence was of very low certainty [<a href="#rid30">30</a>]. (See  <a class="medical medical_review" href="/z/d/html/1232.html" rel="external">"Attention deficit hyperactivity disorder in adults: Epidemiology, clinical features, assessment, and diagnosis", section on 'Clinical manifestations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Driving and work performance</strong> – Although evidence of positive effects on long-term psychosocial outcomes is limited, observational studies have found benefits from stimulant medication on functioning, self-esteem, and work performance [<a href="#rid33">33</a>]. Additionally, while previous studies have found that individuals with ADHD are more likely to be involved in a motor vehicle collision compared with individuals without the disorder, treatment of ADHD with medications lowers the risk of collisions [<a href="#rid34">34,35</a>]. A cohort study of 2,319,450 patients diagnosed and treated for ADHD in the United States compared the risk of a motor vehicle collision in ADHD patients during months when they were and were not receiving ADHD medication [<a href="#rid36">36</a>]. Males and females had a lower risk of a collision when receiving ADHD medication, by 38 percent (odds ratio 0.62, 95% CI 0.56-0.67) and 42 percent (odds ratio 0.58, 95% CI 0.53-0.62), respectively. (See  <a class="medical medical_review" href="/z/d/html/1232.html" rel="external">"Attention deficit hyperactivity disorder in adults: Epidemiology, clinical features, assessment, and diagnosis", section on 'Clinical manifestations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration of effect </strong>– Clinical trials have primarily focused on short-term effects (eg, 12 weeks) of stimulant medications. These trials have consistently shown positive short-term effects.</p><p></p><p class="bulletIndent1">Examples of clinical trials investigating the short-term effects of stimulants include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Amphetamines</strong> – In a trial, 255 adults with ADHD were randomly assigned to treatment with mixed <a class="drug drug_general" data-topicid="99959" href="/z/d/drug information/99959.html" rel="external">amphetamine</a> salts extended-release at dose of 20 mg, 40 mg, 60 mg, or placebo over four weeks [<a href="#rid29">29</a>]. Improvement in symptoms based on the ADHD-Rating Scale were shown at each of the three doses respectively versus placebo.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Methylphenidate</strong> – In a meta-analysis of 16 trials including 3799 subjects with ADHD, individuals treated with extended-release <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">methylphenidate</a> showed greater improvements in self-rated ADHD symptoms as compared with placebo (standardized mean difference -0.37, 95% CI -0.43 to 0.3) [<a href="#rid31">31</a>]. Additionally, improvements as compared with placebo were noted in self-rated quality of life (standardized mean difference -0.15, 95% CI -0.25 to -0.05; six trials, 1888 participants), investigator-rated ADHD symptoms (standardized mean difference -0.42, 95% CI -0.49 to -0.36; 18 trials, 4183 participants), and family- or peer-rated ADHD symptoms (standardized mean difference -0.31, 95% CI -0.48 to -0.14; three trials, 1005 participants). Treatment with extended-release methylphenidate was no better than placebo on “missed days at work.” All outcomes were rated as very low-quality evidence.</p><p></p><p class="bulletIndent2">In another six-week trial, individuals treated with <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">methylphenidate</a> were more likely to experience a 30 percent or more decline in symptoms versus those treated with placebo (68 versus 17 percent) [<a href="#rid37">37</a>].</p><p></p><p class="bulletIndent1">Longer-term data on the efficacy of stimulants in adult ADHD are limited in amount and quality. Results from trials and observational studies suggest that continued stimulant treatment may lead to sustained improvement in ADHD symptoms for at least 24 to 52 weeks. For example:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a 24-week trial, 359 individuals with ADHD were randomly assigned to receive either extended-release <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">methylphenidate</a> (mean dose 0.55 mg/kg) or placebo. A greater proportion of individuals treated with active medication experienced a 30 percent relative improvement in ADHD symptoms as compared with individuals treated with placebo (61 versus 42 percent) [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In an uncontrolled follow-up study, 96 adults with ADHD who improved while taking <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">methylphenidate</a> in randomized trials reported sustained improvements in ADHD symptoms at 30 weeks with continued medication [<a href="#rid38">38</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In another uncontrolled follow-up study, 78 individuals who had improved in response to immediate release <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">methylphenidate</a> showed ongoing improvements in ADHD symptoms and psychosocial functioning at one year [<a href="#rid24">24</a>].</p><p></p><p class="headingAnchor" id="H1272967930"><span class="h3">Adverse effects</span><span class="headingEndMark"> — </span>Stimulant medications are generally well tolerated when taken as directed. Side effects of stimulants reported in adults treated for ADHD include dry mouth, insomnia (particularly if the duration of medication effects extends into the evening or if the medication is taken late during the day), irritability, dysphoria, diminished appetite, weight loss, and headaches [<a href="#rid39">39</a>]. Nontherapeutic effects such as euphoria or elevated mood may lead to misuse of medications. Additionally, exacerbation of existing motor and vocal tics, as well as new onset of tics, has occurred. In a meta-analysis of clinical trials, 10 percent of adults with ADHD treated with stimulant medications discontinued the medication due to adverse events [<a href="#rid40">40</a>].</p><p></p><p>Other effects that may be seen in individuals treated with stimulant medications include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Psychosis</strong> – Psychosis has been reported in individuals who misuse or take excessive amounts of stimulant medication and may be an indication that a stimulant is being misused. Additionally, psychosis may be seen in individuals with a vulnerability to psychosis (eg, comorbid schizophrenia, schizotypal personality disorder, mood disorders with psychosis, history of <a class="drug drug_general" data-topicid="99959" href="/z/d/drug information/99959.html" rel="external">amphetamine</a> induced psychosis) [<a href="#rid41">41</a>]. Otherwise, psychosis appears to be rare in clinical samples of adults with ADHD receiving stimulant treatment.</p><p></p><p class="bulletIndent1">In a study of data from national registries in Sweden, treatment-emergent mania was found to be associated with the initiation of <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">methylphenidate</a> treatment in adults with co-occurring bipolar disorder and ADHD; however, this association was seen only in patients who were not taking a mood stabilizing medication [<a href="#rid42">42</a>]. (See <a class="local">'Bipolar disorder'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiovascular effects </strong>– Consistent elevations in systolic and diastolic blood pressure (3 to 5 mmHg) and heart rate (five beats per minute) have been reported to result from stimulant treatment of ADHD in adults. The increases appear to be correlated, in part, to dose [<a href="#rid43">43</a>]. Longer-term data on the cardiovascular effects of these medications in adults suggest that these effects do not diminish over time. Research on the relationship between treatment with stimulants and cardiac disease or cardiac events has found mixed results:</p><p></p><p class="bulletIndent1">The following studies support the association between use of medications for the treatment of ADHD and the risk of cardiovascular disease: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a case-control study of over 278,000 individuals (age 6 to 64) with ADHD, longer cumulative duration of medication for ADHD as compared with nonuse of medications was associated with a greater risk of cardiovascular disease diagnosis [<a href="#rid44">44</a>]. As examples: </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>At 1 to ≤2 years use, as compared with nonuse, the risk of cardiovascular diseases is adjusted odds ratio 1.09 (95% CI 1.01-1.18).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>At &gt;5 years of use, as compared with nonuse, the risk of cardiovascular disease is adjusted odds ratio 1.23 (95% CI 1.12-1.36).</p><p></p><p class="bulletIndent2">While the association was reported for stimulant medication for up to five years, for nonstimulant medications the association was for less than 1 year only. The strongest associations with any medication for ADHD at five years as compared with nonuse were for hypertension (odds ratio 1.8, 95% CI 1.6-2.1) and arterial disease (odds ratio 1.5, 95% CI 0.96-2.3).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A retrospective analysis of 43,999 patients newly treated with <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">methylphenidate</a>, matched to nonusers of methylphenidate, found a 1.8-fold increase in sudden death or ventricular arrhythmia. The absence of a dose-response relationship suggested that the association between the medication and cardiac events may not be causal [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent1">However, these studies did not find an association: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a meta-analysis of observational studies, an association between treatment for ADHD with stimulant or nonstimulant medications and the risk of cardiovascular disease (ie, hypertension, ischemic heart disease, cerebrovascular disease, heart failure, venous thromboembolism, tachyarrhythmias, and cardiac arrest) across age groups was not supported [<a href="#rid45">45</a>]. Pooled adjusted relative risks between ADHD medication use and any cardiovascular disease was 1.04 (95% CI 0.43-2.48; (seven studies, n &gt;850,000) and 1.59 (95% CI 0.62-4.05; six studies, n &gt;267,000 subjects) in young/middle-aged adults and older adults, respectively.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A retrospective, population-based cohort study of over 150,000 patients treated with <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">methylphenidate</a>, <a class="drug drug_general" data-topicid="99959" href="/z/d/drug information/99959.html" rel="external">amphetamine</a>, or <a class="drug drug_general" data-topicid="8787" href="/z/d/drug information/8787.html" rel="external">atomoxetine</a> did not find an association between stimulant treatment and the risk of sudden cardiovascular events among young and middle-aged adults [<a href="#rid46">46</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Priapism </strong>– Priapism is a rare complication of <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">methylphenidate</a> stimulants in adult males, adolescents, and boys [<a href="#rid47">47-49</a>]. Fifteen cases with a median age 12.5 years (range 8 to 33 years) were reported to the US Food and Drug Administration over a 15 year period [<a href="#rid50">50</a>]. Two cases required surgical treatment. Priapism has also been reported among four patients taking <a class="drug drug_general" data-topicid="99959" href="/z/d/drug information/99959.html" rel="external">amphetamine</a> stimulants [<a href="#rid50">50</a>]; causation is uncertain as these patients were taking other medications thought to cause priapism. The diagnosis and treatment of priapism are discussed in a separate topic. (See  <a class="medical medical_review" href="/z/d/html/6887.html" rel="external">"Priapism"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Potential for misuse or addiction</strong> – Prescription stimulants are subject to misuse, dependence, and/or diversion. Misuse of prescription drugs, including stimulants, is reviewed in detail separately. (See <a class="local">'Substance use and alcohol use disorder'</a> below and  <a class="medical medical_review" href="/z/d/html/15236.html" rel="external">"Prescription drug misuse: Epidemiology, prevention, identification, and management"</a>.)</p><p></p><p class="bulletIndent1">In studies of adults receiving stimulants for ADHD, stimulant treatment does not appear to affect the likelihood of subsequent SUD development, neither increasing SUD risk nor having a protective effect. A meta-analysis of 15 longitudinal studies that compared patients with a history of stimulant-treated ADHD to matched cohorts without stimulant treatment found no association between stimulant treatment history and subsequent substance use, abuse, or dependence [<a href="#rid51">51</a>]. In a national United States survey, 8.9 percent of the participants with a prescription for ADHD medication reported to have sold, traded, or given away their medication [<a href="#rid52">52</a>].</p><p></p><p class="bulletIndent1">However, individuals with recent or current SUDs are believed to be at higher risk of misuse [<a href="#rid53">53,54</a>]. (See  <a class="medical medical_review" href="/z/d/html/108891.html" rel="external">"Alcohol use disorder: Treatment overview"</a> and  <a class="medical medical_review" href="/z/d/html/106878.html" rel="external">"Stimulant use disorder: Treatment overview"</a> and  <a class="medical medical_review" href="/z/d/html/108803.html" rel="external">"Opioid use disorder: Treatment overview"</a>.)</p><p></p><p class="headingAnchor" id="H3296395898"><span class="h3">Counseling on low-risk and risky alcohol use</span><span class="headingEndMark"> — </span>We caution individuals treated with stimulants for ADHD about simultaneous consumption of alcohol and stimulants. We recommend these individuals limit their alcohol use to one to two drinks after the expected therapeutic effects of the simulant have likely ended (ie, in the evening after morning stimulant administration). Prior use of alcohol may have clinically significant interactions with a number of subsequently administered stimulant drugs, including <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">methylphenidate</a> [<a href="#rid55">55</a>] and effects on the medications’ pharmacokinetic and/or pharmacodynamic properties [<a href="#rid55">55</a>] through the production of new psychoactive metabolites [<a href="#rid56">56</a>].</p><p class="headingAnchor" id="H3639273132"><span class="h2">Alternatives to stimulant medications</span></p><p class="headingAnchor" id="H1965465519"><span class="h3">Norepinephrine reuptake inhibitors</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8787" href="/z/d/drug information/8787.html" rel="external">Atomoxetine</a> [<a href="#rid57">57</a>] and <a class="drug drug_general" data-topicid="131244" href="/z/d/drug information/131244.html" rel="external">viloxazine</a> are nonstimulant medications that inhibit reuptake of norepinephrine. These agents have minimal abuse potential and appear to be efficacious in adult ADHD; however, indirect comparison of effect sizes in clinical trials suggest that stimulant medications are more effective [<a href="#rid4">4,6,7</a>]. (See <a class="local">'Stimulants as preferred pharmacologic treatment'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Atomoxetine</strong> – <a class="drug drug_general" data-topicid="8787" href="/z/d/drug information/8787.html" rel="external">Atomoxetine</a> is an effective medication for adult ADHD with little to no abuse potential and is not universally classified as a controlled substance [<a href="#rid58">58</a>].</p><p></p><p class="bulletIndent1">We typically begin treatment with <a class="drug drug_general" data-topicid="8787" href="/z/d/drug information/8787.html" rel="external">atomoxetine</a> at 40 mg given once daily either in the morning or evening. We increase to 80 mg daily after three or four days if the medication is tolerated. We then monitor for an additional four weeks and if the effect is not sufficient we increase to the maximum dose of 100 mg per day. If adequate improvement is not seen after another four weeks, trial of another medication is indicated.</p><p></p><p class="bulletIndent1">The most common side effects observed with <a class="drug drug_general" data-topicid="8787" href="/z/d/drug information/8787.html" rel="external">atomoxetine</a> have included dry mouth, insomnia, nausea, decreased appetite, constipation, decreased libido, erectile dysfunction, urinary hesitancy, dizziness, and sweating [<a href="#rid59">59</a>]. Aggressive behavior or hostility, and the emergence of psychosis or mania may be associated with treatment with atomoxetine [<a href="#rid60">60</a>]. In a six-month trial, patients discontinued medication treatment due to adverse events at a higher rate in the atomoxetine compared with the placebo group (17.2 versus 5.6 percent) [<a href="#rid61">61</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8787" href="/z/d/drug information/8787.html" rel="external">Atomoxetine</a> is rapidly absorbed after oral administration. It is metabolized primarily through the hepatic cytochrome P450 system, through the 2D6 enzyme. There have been reports of hepatoxicity in two patients taking atomoxetine, with both patients recovering upon discontinuation. Atomoxetine can produce QTc prolongation in some individuals. (See  <a class="medical medical_review" href="/z/d/html/5763.html" rel="external">"Cardiac evaluation of patients receiving pharmacotherapy for attention deficit hyperactivity disorder", section on 'Pretreatment clinical evaluation'</a>.)</p><p></p><p class="bulletIndent1">Although there is a “boxed warning” for <a class="drug drug_general" data-topicid="8787" href="/z/d/drug information/8787.html" rel="external">atomoxetine</a> in youth under the age of 25 regarding suicidal behavior, no similar behaviors have been reported in studies of adults with ADHD.</p><p></p><p class="bulletIndent1">Analyses of multiple clinical trials have found <a class="drug drug_general" data-topicid="8787" href="/z/d/drug information/8787.html" rel="external">atomoxetine</a>, as compared with placebo, to reduce core ADHD symptoms (eg, inattention, hyperactivity) as well as improve executive functioning and quality of life in adults.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a meta-analysis of 12 trials including 3375 adults with ADHD, individuals treated with <a class="drug drug_general" data-topicid="8787" href="/z/d/drug information/8787.html" rel="external">atomoxetine</a> had greater reduction in core symptoms of inattention and hyperactivity/impulsivity than those treated with placebo (standard mean difference -0.33, 95% CI -0.43 to -0.23) [<a href="#rid62">62</a>]. However, the overall rate of discontinuation due to adverse effects was greater for atomoxetine than placebo (odds ratio 2.57, 95% CI 1.78-3.71).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In an analysis of industry sponsored trials (nine trials, 3374 individuals) individuals were randomly assigned to treatment with <a class="drug drug_general" data-topicid="8787" href="/z/d/drug information/8787.html" rel="external">atomoxetine</a> or placebo [<a href="#rid63">63</a>]. Over the short term (approximately 12 weeks), the percent of atomoxetine patients meeting criteria for improvement in ADHD symptoms was greater than that achieved by patients assigned to placebo (34.8 versus 22.3 percent). In longer-term analyses (eg, six months), patients assigned to atomoxetine had a greater response rate compared with placebo (43.4 versus 28.0 percent).</p><p></p><p class="bulletIndent2">Longer-term efficacy (six months or longer) has been reported for <a class="drug drug_general" data-topicid="8787" href="/z/d/drug information/8787.html" rel="external">atomoxetine</a>, as compared with placebo, for other outcomes such as executive functioning and quality of life [<a href="#rid61">61,64</a>]. Additionally in an uncontrolled trial including 125 individuals with atomoxetine for ADHD, a mean symptom reduction of 30 percent on the Connors’ Adult ADHD Rating Scale-Investigator Rated: Screening Version was maintained over a mean of 221 weeks [<a href="#rid65">65</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Viloxazine</strong><strong> </strong>–<strong> </strong><a class="drug drug_general" data-topicid="131244" href="/z/d/drug information/131244.html" rel="external">Viloxazine</a> is a nonstimulant medication that acts via selective inhibition of norepinephrine and serotonin reuptake and is approved for treatment of children and adults with ADHD [<a href="#rid66">66,67</a>]. In a trial, 50 patients (35 of them children), were treated with four weeks of <a class="drug drug_general" data-topicid="8787" href="/z/d/drug information/8787.html" rel="external">atomoxetine</a> (mean dose 60 mg/day; range 25 to 100 mg/day), followed by a five-day washout period, then treatment with Viloxazine ER (mean dose 300 mg per day; range 100-600 mg/day) [<a href="#rid68">68</a>]. After four weeks, treatment with viloxazine ER, as compared with atomoxetine, was associated with greater reduction in core ADHD symptoms, as well as fewer side effects, and a preference of 96 percent for continued treatment with viloxazine.</p><p></p><p class="bulletIndent1">We begin <a class="drug drug_general" data-topicid="131244" href="/z/d/drug information/131244.html" rel="external">viloxazine</a> at 200 mg orally once daily in adults with ADHD. We increased by 200 mg weekly to a total daily dose of 600 mg daily. For individuals with severe renal impairment (glomerular filtration rate &lt;30 ml/min) we begin at 100 mg daily and titrate by 50 to 100 mg weekly to 200 mg total.</p><p></p><p class="bulletIndent1">Side effects include insomnia, fatigue, irritability, nausea, headache, elevation of blood pressure or heart rate, activation of mania or hypomania, and possible emergence of suicidal thoughts. We monitor all adults treated with <a class="drug drug_general" data-topicid="131244" href="/z/d/drug information/131244.html" rel="external">viloxazine</a> for the emergence of suicidal thoughts or behaviors at each visit and are especially vigilant during the first few months of treatment and at times of dose changes.</p><p></p><p class="bulletIndent1">Clinical experience with <a class="drug drug_general" data-topicid="131244" href="/z/d/drug information/131244.html" rel="external">viloxazine</a> is limited. In an unpublished trial, 374 adults were randomly assigned to flexible dose of viloxazine (200 to 600 mg) or placebo for six weeks [<a href="#rid66">66</a>]. At treatment end, the reduction on the ADHD Investigator Symptom Rating Scale, an 18-point measure of symptoms, was greater in adults treated with viloxazine as compared with placebo (mean difference -3.7, 95% CI -6.2 to -1.2).</p><p></p><p class="bulletIndent1">Information on administration, dose, titration and adverse effects of <a class="drug drug_general" data-topicid="8787" href="/z/d/drug information/8787.html" rel="external">atomoxetine</a> and <a class="drug drug_general" data-topicid="131244" href="/z/d/drug information/131244.html" rel="external">viloxazine</a> are found on the associated table  (<a class="graphic graphic_table graphicRef50379" href="/z/d/graphic/50379.html" rel="external">table 1</a>).</p><p></p><p class="headingAnchor" id="H3700481790"><span class="h3">Antidepressant medications</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">Bupropion</a>, an atypical antidepressant, and <a class="drug drug_general" data-topicid="9711" href="/z/d/drug information/9711.html" rel="external">nortriptyline</a>, a TCA, have been shown to have efficacy in adults with ADHD. We typically use them as a treatment option for adults with ADHD who have not responded to the above agents. However, we use bupropion in the treatment of individuals with co-occurring active major depression and ADHD as it has established efficacy for both disorders. (See <a class="local">'Depression'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bupropion</strong><strong> </strong>– While <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> appears to be effective for adults with ADHD, clinical effects of bupropion may take up to several weeks to appear.</p><p></p><p class="bulletIndent1">We typically give sustained release <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> beginning at 100 mg in the morning and, if tolerated, we increase to 100 mg twice daily after one to two weeks. We maintain at this dose for three to four weeks. If adequate response is not seen at that time (see <a class="local">'Monitoring'</a> below), we increase in 100 mg increments to a maximum dose of 200 mg twice daily. We monitor at three to four weeks after each dose increase. Bupropion extended-release is given once daily beginning at 150 mg. We increase after several weeks depending on response to 300 mg per day and then 450 mg per day given once daily. We prefer to use the extended-release formulation, as it results in a smoother delivery and lower peak level making side effect of seizure less likely.</p><p></p><p class="bulletIndent1">A meta-analysis of five randomized trials with a total of 349 adult participants with ADHD found that <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> led to a higher response rate (relative risk 1.67, 95% CI 1.23-2.26) and a greater reduction in inattentive and overall ADHD symptoms compared with patients receiving placebo [<a href="#rid69">69</a>]. The rate of trial discontinuation (overall and due to adverse drug effects) did not differ between groups. In another trial, 162 adults with ADHD were randomly assigned to receive eight weeks of up to 450 mg/day of bupropion extended-release or placebo [<a href="#rid70">70</a>]. Individuals in the treatment group had a higher rate of response (defined as 30 percent reduction in investigator-rated ADHD symptoms) than those in the placebo group (53 versus 31 percent). Bupropion was reported to be well tolerated with no serious or unexpected adverse effects and low rate of discontinuation (5 percent).</p><p></p><p class="bulletIndent1">There are no direct comparisons of stimulant and <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> treatment in adult ADHD; comparison of effect sizes from placebo-controlled trials of the drugs suggests that stimulants lead to greater symptom reduction compared with bupropion [<a href="#rid71">71</a>]. The efficacy of bupropion in the treatment of depression and for smoking cessation favors the use of the drug in adults with ADHD and one or both of these conditions.</p><p></p><p class="bulletIndent1">Side effects of <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> include dry mouth, nausea, insomnia, dizziness, anxiety, dyspepsia, sinusitis, and tremor. Bupropion may increase the risk of seizures, particularly with higher doses and shorter-acting formulations and in patients with eating disorders [<a href="#rid72">72</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tricyclic antidepressants </strong>– TCAs appear to be efficacious in adult ADHD [<a href="#rid73">73</a>]. In our clinical experience; however, TCAs are less effective than stimulants and more poorly tolerated than stimulants, <a class="drug drug_general" data-topicid="8787" href="/z/d/drug information/8787.html" rel="external">atomoxetine</a>, or <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a>.</p><p></p><p class="bulletIndent1">With the paucity of data regarding TCAs for the treatment of adult ADHD, dosing is not well established. We typically start at a low dose and increase gradually. As an example, we begin <a class="drug drug_general" data-topicid="9711" href="/z/d/drug information/9711.html" rel="external">nortriptyline</a> at 10 mg daily and increase in 25 mg increments weekly until a therapeutic range is reached (50 to 150 ng/ml). We check therapeutic levels and assure that the individual has a three- to four-week trial at each dose within the therapeutic range. If further increases are needed (eg, due to lack of response), we continue to increase the dose until maximum therapeutic dose is reached (ie, 150 ng/ml), side effects limit further increases, or acceptable response is achieved  (<a class="graphic graphic_table graphicRef50379" href="/z/d/graphic/50379.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent1">In a trial, 41 adults with ADHD were randomized to receive a six-week trial of <a class="drug drug_general" data-topicid="9329" href="/z/d/drug information/9329.html" rel="external">desipramine</a> (target dose 200 mg) or placebo [<a href="#rid73">73</a>]. At treatment end, a greater proportion of individuals in the desipramine group responded as compared with placebo (68 versus 0 percent). A small number of patients responded to a dose less than 100 mg/day; the majority required higher dosing, to a target dose of 200 mg/day for efficacy.</p><p></p><p class="bulletIndent1">Benefits of TCAs treatment include their effectiveness in treating co-occurring depression or anxiety with ADHD, lack of abuse liability, and single daily dosing. However, TCAs have greater side effects as compared with other medications that are effectively used in the treatment of ADHD. Additionally, TCAs may be lethal in overdose. Clinical trials comparing their efficacy have not been conducted.</p><p></p><p class="bulletIndent1">Due to potential cardiovascular effects (eg, hypotension, hypertension, tachycardia, QTc prolongation) and cardiotoxicity of TCAs, we check ECG at baseline and at each dose increase as well as every four to six months during maintenance treatment. Although plasma levels of TCAs do not appear to be related to efficacy, monitoring plasma levels at higher doses may help to avoid toxicity or overdose. Risks of cardiotoxicity, particularly with overdose, should prompt careful monitoring of TCA treatment. (See  <a class="medical medical_review" href="/z/d/html/1717.html" rel="external">"Tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects"</a>.)</p><p></p><p class="headingAnchor" id="H2699025471"><span class="h1">INITIAL TREATMENT FOR SPECIFIC POPULATIONS</span></p><p class="headingAnchor" id="H84268851"><span class="h2">Co-occurring disorders</span><span class="headingEndMark"> — </span>We generally address comorbid disorders concurrently with attention deficit hyperactivity disorder (ADHD) treatment. However, in some disorders, such as active substance use disorder (SUD), we often address the co-occurring disorder prior to treating ADHD. (See  <a class="medical medical_review" href="/z/d/html/1232.html" rel="external">"Attention deficit hyperactivity disorder in adults: Epidemiology, clinical features, assessment, and diagnosis", section on 'Comorbidity'</a>.)</p><p class="headingAnchor" id="H1446881504"><span class="h3">Substance use and alcohol use disorder</span><span class="headingEndMark"> — </span>Polysubstance use is common in adults with ADHD [<a href="#rid74">74</a>]. While there are few reports of severe health consequences due to acute co-administration of alcohol and stimulants, some studies have documented that that administration of stimulants in conjunction with alcohol use results in potential risks beyond the additive respective behavioral effects of the substances [<a href="#rid74">74</a>].</p><p class="headingAnchor" id="H1429310325"><span class="h4">Active substance use disorder</span><span class="headingEndMark"> — </span>For individuals with active SUD, we treat the co-occurring SUD until stabilized prior to treating ADHD [<a href="#rid74">74</a>].</p><p>However, clinical trials of stimulant treatment in ADHD patients with an active co-occurring SUD (nicotine, cocaine, and opioid dependence) have found mixed efficacy results [<a href="#rid75">75-79</a>]. As an example, a clinical trial in 126 adults with both ADHD and cocaine use disorder randomly assigned patients to receive extended-release <a class="drug drug_general" data-topicid="8723" href="/z/d/drug information/8723.html" rel="external">dextroamphetamine-amphetamine</a> (60 or 80 mg/day) or placebo [<a href="#rid75">75</a>]. More patients achieved at least a 30 percent reduction in ADHD symptom severity in the 60 and 80 mg/day medication groups compared with placebo (75.0 and 58.1 versus 39.5 percent). The odds of a cocaine-negative week were higher in the 80 and 60 mg/day groups (odds ratios 5.46 and 2.92, respectively) compared with placebo.</p><p class="headingAnchor" id="H1453669968"><span class="h4">History of substance use disorder</span><span class="headingEndMark"> — </span>To avoid the risks of misuse, addiction, or diversion of prescribed stimulants in adults with ADHD and a history of SUD, we suggest first-line treatment with <a class="drug drug_general" data-topicid="8787" href="/z/d/drug information/8787.html" rel="external">atomoxetine</a>, a nonstimulant medication that inhibits presynaptic norepinephrine reuptake. Atomoxetine is effective for adult ADHD compared with placebo [<a href="#rid62">62</a>] and has been used safely in patients with co-occurring ADHD and an SUD [<a href="#rid80">80,81</a>]. Atomoxetine has little to no abuse potential [<a href="#rid58">58</a>]. <a class="drug drug_general" data-topicid="131244" href="/z/d/drug information/131244.html" rel="external">Viloxazine</a>, a nonstimulant medication with similar properties is an acceptable alternative  (<a class="graphic graphic_algorithm graphicRef140086" href="/z/d/graphic/140086.html" rel="external">algorithm 1</a>). (See <a class="local">'Alternatives to stimulant medications'</a> above.)</p><p class="headingAnchor" id="H1509714063"><span class="h3">Depression</span><span class="headingEndMark"> — </span>We typically treat individuals with comorbid major depressive disorder with <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a>, an antidepressant with established efficacy for both disorders [<a href="#rid69">69</a>]. Subsequent treatment of individuals with comorbid depression and ADHD who do not respond to bupropion may be found below and in the associated algorithm  (<a class="graphic graphic_algorithm graphicRef140088" href="/z/d/graphic/140088.html" rel="external">algorithm 2</a>). (See <a class="local">'For co-occurring disorders'</a> below.)</p><p>There are no clinical trials comparing the efficacy of medication treatments for co-occurring depression and ADHD in adults. Information on dosing <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> is described in a table  (<a class="graphic graphic_table graphicRef50379" href="/z/d/graphic/50379.html" rel="external">table 1</a>). Administration, pharmacology and side effects of bupropion for depression can be found elsewhere. (See <a class="local">'Antidepressant medications'</a> above and  <a class="medical medical_review" href="/z/d/html/85816.html" rel="external">"Atypical antidepressants: Pharmacology, administration, and side effects", section on 'Bupropion'</a>.)</p><p class="headingAnchor" id="H323550406"><span class="h3">Anxiety disorders</span><span class="headingEndMark"> — </span>We typically treat individuals presenting with ADHD with comorbid anxiety disorder (eg, generalized anxiety disorder or social anxiety disorder) with the combination of a stimulant [<a href="#rid5">5</a>] and a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) [<a href="#rid82">82</a>]. We typically address the anxiety first by starting the SSRI or SNRI, and when the anxiety has improved we add a stimulant medication  (<a class="graphic graphic_algorithm graphicRef140088" href="/z/d/graphic/140088.html" rel="external">algorithm 2</a>). (See <a class="local">'Choosing a stimulant'</a> above.)</p><p>The combination of a serotonergic medication with a stimulant can lead to excessive serotonin activity. We monitor individuals treated with the combination of serotonergic reuptake inhibitor and stimulant for the presence of serotonin syndrome, a potentially life threatening syndrome caused by excessive serotonin activity. Separate topics discuss stimulants, SSRIs, and SNRIs, as well as the serotonin syndrome. (See  <a class="medical medical_review" href="/z/d/html/101879.html" rel="external">"Generalized anxiety disorder in adults: Management", section on 'SRIs as preferred initial therapy'</a> and  <a class="medical medical_review" href="/z/d/html/505.html" rel="external">"Pharmacotherapy for social anxiety disorder in adults", section on 'Monotherapy'</a>.)</p><p>There are no clinical trials comparing efficacy among medication treatments for co-occurring anxiety disorders and ADHD in adults.</p><p class="headingAnchor" id="H441964798"><span class="h3">Bipolar disorder</span><span class="headingEndMark"> — </span>In individuals with comorbid ADHD and bipolar disorder, we stabilize the mood symptoms (eg, mania, hypomania) and establish therapeutic levels of mood stabilizing medication prior to treatment for ADHD [<a href="#rid83">83</a>]. The risk of precipitation of manic symptoms in individuals treated with stimulant medications appears to be attenuated by having a stable bipolar status and being on mood stabilizing medications. In a retrospective analysis of data from the Sweden’s national health registries, adults with bipolar disorder initiating stimulant treatment while not on a mood stabilizing medication had an increased risk of treatment-emergent mania (hazard ratio 6.7, 95% CI 2.0-22.4), while adults who were already receiving a mood stabilizing treatment did not (hazard ratio 0.6, 95% CI 0.4-0.9) [<a href="#rid42">42</a>].</p><p class="headingAnchor" id="H2735724759"><span class="h2">Pregnancy</span><span class="headingEndMark"> — </span>When medications are used, we prefer to use <a class="drug drug_general" data-topicid="99959" href="/z/d/drug information/99959.html" rel="external">amphetamine</a> formulations in this population. Other options include a drug holiday (for those who can reasonably tolerate it) through at least the first trimester. For patients who have a history of doing well on <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">methylphenidate</a> and/or cannot tolerate an amphetamine, the clinician must weigh the risk to the mother and baby if the mother is not treated.</p><p>A small increased risk of cardiac malformations has been associated with intrauterine exposure of the fetus to <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">methylphenidate</a> [<a href="#rid84">84</a>]. The association with cardiac malformations was not found in infants with intrauterine exposure to amphetamines. Analysis of data in a pooled sample of 1,813,894 publicly insured pregnancies in the United States and 2,560,069 infants in five Nordic countries found a higher rate of cardiac malformations in infants exposed to methylphenidate during the first trimester compared with unexposed infants (relative risk 1.28, 95% CI 1.00-1.64) [<a href="#rid84">84</a>]. Exposed and unexposed samples were balanced in rates of numerous potentially confounding variables, but the influence of unmeasured confounders could not be ruled out.</p><p>Furthermore, the proportion of reproductive-aged, privately insured women in the United States who are treated with medication for ADHD has increased over the past two decades [<a href="#rid85">85</a>]. An analysis of data on approximately 4.6 million women per year, age 15 to 44 years, found that the proportion treated with an ADHD medication increased by 344 percent over a 12-year period.</p><p class="headingAnchor" id="H1124281101"><span class="h1">MONITORING</span><span class="headingEndMark"> — </span>We monitor for positive and negative effects of medications and adverse effects at each visit [<a href="#rid86">86</a>].</p><p class="headingAnchor" id="H379515003"><span class="h2">Defining response</span><span class="headingEndMark"> — </span>We work closely with the patient to establish what constitutes response (eg, reduction in attention deficit hyperactivity disorder [ADHD] symptoms and/or improved overall functioning) and the time course for improvement. While treatment success may be defined as remission of all ADHD symptoms, improvement in the symptoms may be clinically significant and represent observable change from baseline [<a href="#rid86">86</a>] (see <a class="local">'Monitoring'</a> above and <a class="local">'Monitoring for symptomatic improvement'</a> below and <a class="local">'Monitoring for adverse effects'</a> below). Improvement in overall functioning generally follows improvement of attention-related symptoms. Therefore, we suggest monitoring both through the use of repeat administration of rating scales and the assessment of overall functioning with regard to work and relationships. We also obtain permission to gather collateral information from a reliable informant. Due to such issues as psychiatric comorbidity, clinicians and patients may not note immediate and/or sustained overall improvement in psychosocial functioning.</p><p class="headingAnchor" id="H942889358"><span class="h2">Monitoring for symptomatic improvement</span><span class="headingEndMark"> — </span>We use ADHD symptom checklists to monitor symptoms throughout treatment. We find it useful to get input from other informants that are familiar with the patient as well as input from real-world collateral information such as job performance evaluation, attendance records, and grades. These may offer measures of progress tied to various performance venues that may be affected by ADHD treatment [<a href="#rid87">87</a>].</p><p class="headingAnchor" id="H1741597598"><span class="h3">Instruments for monitoring response to treatment</span><span class="headingEndMark"> — </span>We typically use the Conners’ Adult ADHD Rating Scales [<a href="#rid88">88</a>] for diagnosis and determining symptom severity. We often supplement this with specific psychiatric rating scales for depression and anxiety. In addition, for patients with severe executive dysfunction, we often use the Barkley Deficits in Executive Function Scale to identify targets for treatment and monitor over time  (<a class="graphic graphic_table graphicRef93441" href="/z/d/graphic/93441.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/1232.html" rel="external">"Attention deficit hyperactivity disorder in adults: Epidemiology, clinical features, assessment, and diagnosis", section on 'Assessment'</a> and  <a class="medical medical_review" href="/z/d/html/82780.html" rel="external">"Attention deficit hyperactivity disorder in adults: Psychotherapy", section on 'Monitoring'</a>.)</p><p>Other reliable scales include the Reliable Change Index [<a href="#rid89">89</a>], Barkley ADHD Rating Scale IV, and the Functional Impairment Scale for Adults [<a href="#rid90">90-92</a>]. The Wender-Reimherr Adult Attention Deficit Disorder Scale [<a href="#rid93">93,94</a>] has subscales measuring temper, affective lability, and emotional overreactivity. The Weiss Functional Impairment Rating Scale [<a href="#rid95">95</a>] is useful for assessing the domain and severity of functional impairment. Other domains that can be used for monitoring treatment response include quality of life, executive functions, and processing speed [<a href="#rid96">96-98</a>].</p><p class="headingAnchor" id="H2689554835"><span class="h2">Monitoring for adverse effects</span><span class="headingEndMark"> — </span>Once the individual is on the initial target dose of medication, we see them in monthly follow-up visits until symptoms are stabilized. At each visit, we check blood pressure and pulse and address any abnormalities accordingly. We monitor ECG and work directly with a cardiologist in all individuals with baseline cardiac abnormalities. (See <a class="local">'Pretreatment evaluation and contraindications'</a> above and <a class="local">'Adverse effects'</a> above.)</p><p class="headingAnchor" id="H400096588"><span class="h1">SUBSEQUENT TREATMENT</span></p><p class="headingAnchor" id="H4165327773"><span class="h2">For robust response</span><span class="headingEndMark"> — </span>If a robust response is seen, the timing of stimulant use may still require adjustment. The negative effects of attention deficit hyperactivity disorder (ADHD) differ across adults. We work with the individual to monitor improvement, and assist the patient in determining if medication needs adjustment for vocational, educational, or other activities. Some adults may benefit from drug holidays on weekends or holidays. However, minimal data support this approach.</p><p>Although some adults may need stimulants for a time-limited period, others may need them indefinitely. (See <a class="local">'Treatment duration and continuity'</a> below.)</p><p class="headingAnchor" id="H1301111754"><span class="h2">For suboptimal (partial or minimal) response</span><span class="headingEndMark"> — </span>For individuals with a suboptimal response to initial treatment, we review the accuracy of the diagnosis, the presence of comorbid disease and adherence to medication. We address these as indicated. (See <a class="local">'Co-occurring disorders'</a> above.)</p><p>Augmentation strategies for patients who experienced a suboptimal response to first-line medication treatment are limited.<strong> </strong>Our choice of subsequent management (eg, adjunctive psychotherapy, pharmacologic management) depends, in part, on patient preference and availability of treatment.</p><p class="headingAnchor" id="H3346188317"><span class="h3">Adjunctive psychotherapy</span><span class="headingEndMark"> — </span>For all individuals who were not started on combination treatment who are now agreeable to psychotherapy, we augment a suboptimal response to medication with cognitive-behavioral therapy (CBT) targeting executive functioning. (See <a class="local">'Preference for combination medication and CBT'</a> above and  <a class="medical medical_review" href="/z/d/html/82780.html" rel="external">"Attention deficit hyperactivity disorder in adults: Psychotherapy"</a>.)</p><p class="headingAnchor" id="H1494137769"><span class="h3">For noncomorbid ADHD</span><span class="headingEndMark"> — </span>For adults with noncomorbid ADHD who continue to experience clinically significant symptoms despite initial treatment with amphetamines, (and who are unwilling to augment with psychotherapy, or if it is unavailable, or has been ineffective) we suggest changing medication to a <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">methylphenidate</a> product. No washout or tapering is necessary in switching from one stimulant preparation to another. Our transitioning dose in switching from one stimulant to another is based on whether the switch is due to lack of response or side effects:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lack of response</strong> – If the medication is being switched due to inadequate response without side effects, we suggest initiation of the new stimulant at a dose that is equivalent to or slightly lower than the dose of the current stimulant.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Side effects</strong> – If the medication is being switched due to side effects or intolerance of the initial stimulant, we suggest retitration of the new stimulant starting at the lowest or a much lower equivalent dose than the current stimulant.</p><p></p><p>Equivalent initial stimulant doses, onset and duration of effect of stimulants used in adult ADHD are listed in the table  (<a class="graphic graphic_table graphicRef50379" href="/z/d/graphic/50379.html" rel="external">table 1</a>).</p><p>For patients who do not experience an adequate response to (or are unable to tolerate) a therapeutic dose of either stimulant, we favor successive trials of other nonstimulant medications followed by trials of <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> and tricyclic antidepressants (TCAs) (see <a class="local">'Alternatives to stimulant medications'</a> above). If none of these agents are sufficiently effective, we occasionally use an alpha-2 agonist such as <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">clonidine</a> or <a class="drug drug_general" data-topicid="8510" href="/z/d/drug information/8510.html" rel="external">guanfacine</a>, based on their efficacy in treating children with ADHD. (See <a class="local">'Treatments with limited supporting data in adult ADHD'</a> below.)</p><p class="headingAnchor" id="H1760250661"><span class="h3">For co-occurring disorders</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Substance use and substance use disorder (SUD)</strong> – For adults with ADHD and a history of an SUD who cannot tolerate or do not respond to treatment with <a class="drug drug_general" data-topicid="8787" href="/z/d/drug information/8787.html" rel="external">atomoxetine</a>, we suggest treatment with <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a>. Clinical trials have found bupropion to reduce overall symptoms of ADHD compared with placebo [<a href="#rid69">69</a>]. Additionally, bupropion has been used in the treatment of nicotine and cocaine dependence, decreasing the craving often associated with these disorders [<a href="#rid99">99-101</a>]. (See <a class="local">'For noncomorbid ADHD'</a> above.)</p><p></p><p class="bulletIndent1">In cases where <a class="drug drug_general" data-topicid="8787" href="/z/d/drug information/8787.html" rel="external">atomoxetine</a> and <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> are not effective and there is not a history of stimulant abuse we consider a long-acting <a class="drug drug_general" data-topicid="99959" href="/z/d/drug information/99959.html" rel="external">amphetamine</a> with careful monitoring for signs of misuse, diversion, or addiction. (See  <a class="medical medical_review" href="/z/d/html/15236.html" rel="external">"Prescription drug misuse: Epidemiology, prevention, identification, and management"</a> and  <a class="medical medical_review" href="/z/d/html/16754.html" rel="external">"Continuing care for addiction: Components and efficacy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Depression </strong>– For<strong> </strong>adults with ADHD and depression whose ADHD symptoms do not respond to treatment with <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a>, we suggest treatment with the combination of a long-acting stimulant for ADHD and a selective serotonin reuptake inhibitor (SSRI) or a serotonin-norepinephrine reuptake inhibitor (SNRI) for depression. We are careful in prescribing the combination of an SSRI and a stimulant due to the possibility of serotonin syndrome. (See <a class="local">'Anxiety disorders'</a> above and  <a class="medical medical_review" href="/z/d/html/301.html" rel="external">"Serotonin syndrome (serotonin toxicity)"</a>.)</p><p></p><p class="bulletIndent1">If the combination of an SSRI or an SNRI and a stimulant is ineffective (or due to adverse effects) a TCA is a reasonable alternative. Tricyclics have demonstrated efficacy in ADHD similar to their efficacy in depression [<a href="#rid73">73</a>] and similar to <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a>’s treatment of ADHD, but with more side effects  (<a class="graphic graphic_table graphicRef62488" href="/z/d/graphic/62488.html" rel="external">table 3</a>). (See <a class="local">'For noncomorbid ADHD'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anxiety disorders </strong>– For adults with ADHD and co-occurring generalized anxiety disorder or social anxiety disorder whose ADHD symptoms do not respond to treatment with a long-acting stimulant combined with an SSRI or SNRI, we suggest treatment for both conditions with <a class="drug drug_general" data-topicid="8787" href="/z/d/drug information/8787.html" rel="external">atomoxetine</a>. Atomoxetine has been shown to have efficacy for both ADHD and anxiety, in the form of social anxiety disorder, in adults [<a href="#rid58">58,102-104</a>]. (See <a class="local">'Norepinephrine reuptake inhibitors'</a> above.)</p><p></p><p class="bulletIndent1">If <a class="drug drug_general" data-topicid="8787" href="/z/d/drug information/8787.html" rel="external">atomoxetine</a> is poorly tolerated or ineffective, we typically treat with a TCA, such as <a class="drug drug_general" data-topicid="9711" href="/z/d/drug information/9711.html" rel="external">nortriptyline</a>. Clinical trials have shown TCAs to be effective in both ADHD [<a href="#rid73">73</a>] and generalized anxiety disorder [<a href="#rid82">82</a>], although with somewhat greater side effects than other ADHD medication. TCAs have not been subject to clinical trials in patients with co-occurring ADHD and generalized anxiety disorder. (See  <a class="medical medical_review" href="/z/d/html/101879.html" rel="external">"Generalized anxiety disorder in adults: Management", section on 'Limited role of alternatives to SRIs as initial treatment'</a>.)</p><p></p><p class="bulletIndent1">For adults with ADHD co-occurring with <strong>both</strong> depression and an anxiety disorder, who cannot tolerate or do not respond to treatment with the combination of a stimulant and an SSRI or SNRI, we suggest treatment with a TCA for ADHD and both comorbid disorders. (See <a class="local">'Anxiety disorders'</a> above.)</p><p></p><p class="bulletIndent1">Medication augmentation strategies have been tested in the treatment of ADHD in children/adolescents (eg, stimulants plus <a class="drug drug_general" data-topicid="8510" href="/z/d/drug information/8510.html" rel="external">guanfacine</a> extended-release); however, augmentation in adults with ADHD is not supported by research data nor by our clinical experience. (See  <a class="medical medical_review" href="/z/d/html/621.html" rel="external">"Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents"</a>.)</p><p></p><p class="headingAnchor" id="H1307201855"><span class="h3">Treatments with limited supporting data in adult ADHD</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alpha-2 adrenergic agonists</strong> – Little is known about the efficacy, safety, and tolerability of alpha-2-adrenergic agonists <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">clonidine</a> and <a class="drug drug_general" data-topicid="8510" href="/z/d/drug information/8510.html" rel="external">guanfacine</a> in adults with ADHD. Small clinical trials have not shown these medications to reduce ADHD symptoms in adults compared with placebo [<a href="#rid105">105,106</a>]. The medications have been found to be efficacious in trials with children and adolescents with ADHD, in particular for impulsivity and hyperactivity, for whom they are generally used third-line, or for certain clinical subgroups. (See  <a class="medical medical_review" href="/z/d/html/621.html" rel="external">"Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents", section on 'Alpha-2-adrenergic agonists'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Venlafaxine</strong> – <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">Venlafaxine</a>, a serotonin-norepinephrine reuptake inhibitor antidepressant, may be mildly efficacious in reducing ADHD symptoms. A clinical trial of venlafaxine in 44 adults with ADHD did not find a statistically significant reduction in ADHD symptoms compared with placebo [<a href="#rid107">107</a>]. A greater proportion of patients receiving venlafaxine experienced a 25 percent or greater reduction in ADHD symptoms compared with patients on placebo (75 versus 20 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>SSRI </strong>– While SSRI are often used along with stimulant medications in the treatment of comorbid ADHD with depression, there are few clinical trials of SSRI antidepressants in adults with ADHD. A randomized trial of 98 adults with ADHD and a lifetime diagnosis of an depression or anxiety disorder found no difference in the intent to treat analysis of change in ADHD symptoms among groups treated with either 40 mg/day of <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">paroxetine</a>, 20 mg twice daily of <a class="drug drug_general" data-topicid="9341" href="/z/d/drug information/9341.html" rel="external">dextroamphetamine</a>, or placebo [<a href="#rid108">108</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Solriamfetol</strong><strong> </strong>–<strong> </strong><a class="drug drug_general" data-topicid="120816" href="/z/d/drug information/120816.html" rel="external">Solriamfetol</a>, a selective dopamine and norepinephrine reuptake inhibitor that is used for the treatment of sleepiness in individuals with narcolepsy may be effective in the treatment of adults with ADHD. In a trial, 60 adult subjects with ADHD were randomly assigned to six weeks of treatment with solriamfetol (75 or 150 mg/day) versus placebo [<a href="#rid109">109</a>]. At study endpoint, mean improvement as measured by the adult ADHD Investigator Symptom Rating Scale (AISRS) was greater in those treated with medication as compared with those that received placebo (mean difference AISRS -7.6 versus -2.1, respectively). Additionally, at six weeks, a greater percentage of individuals in the treatment group, as compared with those in the placebo group had Clinical Global Impression ratings of much or very much improved (45 versus 6 percent) and met criteria for remission (24 versus 3 percent). Adverse effects were more common in the treatment group as compared with the placebo group for decreased appetite, headache, gastrointestinal disturbance, insomnia, increased energy, and cardiovascular and neurologic effects. All reported adverse effects were either mild or moderate in severity. Further research confirming the efficacy and tolerability of solriamfetol is suggested.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monoamine oxidase inhibitor antidepressants (MAOIs)</strong> – Clinical trials of MAOIs have shown mixed results in adult ADHD. Patients with ADHD, a disorder characterized by impulsivity and inattention, may be poor candidates for treatment with these medications, which require dietary and other restrictions to avoid serious adverse events. (See  <a class="medical medical_review" href="/z/d/html/1715.html" rel="external">"Monoamine oxidase inhibitors (MAOIs): Pharmacology, administration, safety, and side effects"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neurostimulation </strong>– Transcranial direct current stimulation (tDCS), a noninvasive brain stimulation technique, may improve symptoms of inattention in adults with ADHD who are not taking stimulant or nonstimulant medications. In a randomized trial, 64 individuals with ADHD were treated with 28 sessions (over four weeks) of daily home-based tDCS versus sham tDCS to the right dorsolateral prefrontal cortex [<a href="#rid110">110</a>]. At the end of treatment, individuals receiving tDCS scored lower on measures of inattention (Adult ADHD Self-report scale [36 points, nine questions]) than those receiving sham tDCS (18.9 versus 23.6, respectively). However, effects on hyperactivity-impulsivity, depression, or anxiety symptoms were similar between groups. Further studies evaluating the effects of tDCS for adults with ADHD, including intensity, duration and number of sessions are needed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other agents and complementary or alternative treatments</strong> – Trials of L-deprenyl [<a href="#rid111">111</a>], pargyline [<a href="#rid112">112</a>], <a class="drug drug_general" data-topicid="10157" href="/z/d/drug information/10157.html" rel="external">modafinil</a> [<a href="#rid113">113</a>], and cholinesterase inhibitors [<a href="#rid114">114</a>] have provided little evidence of efficacy of these agents in treating ADHD in adults.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cannabinoids and cannabinoid products</strong> – Despite common belief that cannabinoids and cannabinoid products, including tetrahydrocannabinol (marijuana) have benefits for ADHD, few studies support the drug’s effectiveness for ADHD in adults. Additionally, cannabis use appears to acutely impair cognitive functions such as attention, concentration, and episodic memory [<a href="#rid115">115-117</a>]. These effects are time limited and dependent on dose, route of administration, and degree of tolerance.</p><p></p><p class="bulletIndent2">In a trial 30 adults with ADHD were randomly assigned to treatment with pharmaceutical delta-9-tetrahydrocannabinol (THC):cannabidiol (CBD) versus placebo [<a href="#rid53">53</a>]. Results showed similar effects on primary outcome of ADHD symptoms. At this time, marijuana or other cannabinoids cannot be safely recommended for the treatment of ADHD.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Micronutrients </strong>– There are few clinical trials of complementary/alternative treatments for adult ADHD. In a randomized trial of 80 adults with ADHD, micronutrients (vitamins and minerals) were compared with placebo over eight weeks [<a href="#rid118">118</a>]. Subjects receiving micronutrients were rated by themselves and observers as improved at the end of the trial. Clinician ratings found mixed results, with some ADHD scales showing improvement and others not.</p><p></p><p class="headingAnchor" id="H4036758016"><span class="h1">TREATMENT DURATION AND CONTINUITY</span><span class="headingEndMark"> — </span>The negative effects of attention deficit hyperactivity disorder (ADHD) differ across adults. Some adults may need stimulants for a time-limited period, while others may need them indefinitely. In some cases, drug holidays on weekends or holidays are useful. After providing information about the potential benefits and adverse events associated with stimulant treatment of ADHD, we advocate shared decision-making with the clinician reviewing potential therapeutic options and possibly making a recommendation. As with other clinical decisions described in this report and unless contraindicated, the adult patient has the final word in deciding which of the therapeutic options to follow.</p><p class="headingAnchor" id="H3019411958"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/117871.html" rel="external">"Society guideline links: Attention deficit hyperactivity disorder"</a>.)</p><p class="headingAnchor" id="H4010617008"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial treatment for most</strong> – For most adults with attention deficit hyperactivity disorder (ADHD), we suggest initial treatment with a combination of medication management and cognitive-behavioral therapy (CBT) targeting executive dysfunction, rather than either treatment alone (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>)  (<a class="graphic graphic_algorithm graphicRef140088" href="/z/d/graphic/140088.html" rel="external">algorithm 2</a>). (See <a class="local">'Initial Treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Amphetamines as initial pharmacologic treatment </strong>– For most adults with ADHD, we suggest initial pharmacologic management with an <a class="drug drug_general" data-topicid="99959" href="/z/d/drug information/99959.html" rel="external">amphetamine</a> rather than <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">methylphenidate</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>)  (<a class="graphic graphic_table graphicRef50379" href="/z/d/graphic/50379.html" rel="external">table 1</a>). (See <a class="local">'Choosing a stimulant'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacologic treatment for specific populations </strong>–<strong> </strong>Alternative medication and treatments may be the preferred initial therapy in some patients. (See <a class="local">'Alternatives to stimulant medications'</a> above and <a class="local">'Initial treatment for specific populations'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>For co-occurring substance use or substance use disorder (SUD)</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In individuals with an active SUD and comorbid ADHD, we stabilize the SUD prior to treating ADHD. (See <a class="local">'Active substance use disorder'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For individuals with a history of SUD or substance misuse (eg, benzodiazepines, alcohol, opioids, stimulants), we suggest first-line choice of treatment with the nonstimulant <a class="drug drug_general" data-topicid="8787" href="/z/d/drug information/8787.html" rel="external">atomoxetine</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>)  (<a class="graphic graphic_algorithm graphicRef140086" href="/z/d/graphic/140086.html" rel="external">algorithm 1</a>). (See <a class="local">'History of substance use disorder'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Co-occurring depression </strong>– For adults with ADHD and co-occurring depression, we treat with <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a>. Bupropion has evidence of efficacy in both patients with ADHD and in patients with depression (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Depression'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Co-occurring anxiety </strong>– For adults with ADHD and co-occurring generalized or social anxiety disorders, we treat the disorders at the same time with a combination of a stimulant and a selective serotonin reuptake inhibitor (SSRI). We typically start the SSRI first and the stimulant when the anxiety is lessened. (See <a class="local">'Anxiety disorders'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pregnancy </strong>– For pregnant patients, we avoid <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">methylphenidate</a> when possible due to the risks to the fetus. We consider a drug holiday in pregnancy (for those who can reasonably tolerate it) at least through the first trimester. When medications are used, we prefer to use amphetamines. (See <a class="local">'Pregnancy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subsequent treatment</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>For robust response</strong> – If a robust response is seen, the timing of stimulant use may still require adjustment particularly for vocational activities and educational activities. (See <a class="local">'For robust response'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Partial response </strong>–<strong> </strong>For individuals with a suboptimal response to initial treatment we review the accuracy of the diagnosis, the presence of comorbid disease and adherence to medication. We address these as indicated. (See <a class="local">'For suboptimal (partial or minimal) response'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Adjunctive psychotherapy</strong> – For individuals initially treated with medication alone who have a suboptimal response, we suggest augmentation with CBT targeting executive functioning (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Combination therapy with CBT and pharmacotherapy appears to be the most efficacious treatment for adults with ADHD. (See <a class="local">'Adjunctive psychotherapy'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Medication adjustment</strong> – For adults with noncomorbid ADHD who continue to experience clinically significant symptoms despite treatment with amphetamines (either in conjunction with cognitive processing therapy or when CBT is not available), we suggest changing treatment to a <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">methylphenidate</a> product (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'For noncomorbid ADHD'</a> above.)</p><p></p><p class="bulletIndent3">For individuals with poor response or lack of tolerance to two prior stimulants, we favor successive trials of <a class="drug drug_general" data-topicid="8787" href="/z/d/drug information/8787.html" rel="external">atomoxetine</a>, <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a>, or a tricyclic antidepressant such as <a class="drug drug_general" data-topicid="9711" href="/z/d/drug information/9711.html" rel="external">nortriptyline</a> in addition to augmentation with CBT. Only limited data support these medications for treatment of ADHD in adults.</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Fayyad J, De Graaf R, Kessler R, et al. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry 2007; 190:402.</a></li><li><a class="nounderline abstract_t">Barkley RA, Fischer M, Smallish L, Fletcher K. The persistence of attention-deficit/hyperactivity disorder into young adulthood as a function of reporting source and definition of disorder. J Abnorm Psychol 2002; 111:279.</a></li><li><a class="nounderline abstract_t">Faraone SV, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med 2006; 36:159.</a></li><li><a class="nounderline abstract_t">Faraone SV, Glatt SJ. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J Clin Psychiatry 2010; 71:754.</a></li><li><a class="nounderline abstract_t">Mészáros A, Czobor P, Bálint S, et al. Pharmacotherapy of adult attention deficit hyperactivity disorder (ADHD): a meta-analysis. Int J Neuropsychopharmacol 2009; 12:1137.</a></li><li><a class="nounderline abstract_t">Bitter I, Angyalosi A, Czobor P. Pharmacological treatment of adult ADHD. Curr Opin Psychiatry 2012; 25:529.</a></li><li><a class="nounderline abstract_t">Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry 2018; 5:727.</a></li><li><a class="nounderline abstract_t">Solanto MV, Marks DJ, Wasserstein J, et al. Efficacy of meta-cognitive therapy for adult ADHD. Am J Psychiatry 2010; 167:958.</a></li><li><a class="nounderline abstract_t">Safren SA, Sprich S, Mimiaga MJ, et al. Cognitive behavioral therapy vs relaxation with educational support for medication-treated adults with ADHD and persistent symptoms: a randomized controlled trial. JAMA 2010; 304:875.</a></li><li><a class="nounderline abstract_t">Young Z, Moghaddam N, Tickle A. The Efficacy of Cognitive Behavioral Therapy for Adults With ADHD: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Atten Disord 2020; 24:875.</a></li><li><a class="nounderline abstract_t">Cherkasova MV, French LR, Syer CA, et al. Efficacy of Cognitive Behavioral Therapy With and Without Medication for Adults With ADHD: A Randomized Clinical Trial. J Atten Disord 2020; 24:889.</a></li><li><a class="nounderline abstract_t">Young S, Khondoker M, Emilsson B, et al. Cognitive-behavioural therapy in medication-treated adults with attention-deficit/hyperactivity disorder and co-morbid psychopathology: a randomized controlled trial using multi-level analysis. Psychol Med 2015; 45:2793.</a></li><li><a class="nounderline abstract_t">Emilsson B, Gudjonsson G, Sigurdsson JF, et al. Cognitive behaviour therapy in medication-treated adults with ADHD and persistent symptoms: a randomized controlled trial. BMC Psychiatry 2011; 11:116.</a></li><li><a class="nounderline abstract_t">Pan MR, Zhang SY, Qiu SW, et al. Efficacy of cognitive behavioural therapy in medicated adults with attention-deficit/hyperactivity disorder in multiple dimensions: a randomised controlled trial. Eur Arch Psychiatry Clin Neurosci 2022; 272:235.</a></li><li><a class="nounderline abstract_t">Wettstein RKRW, Klabbers Y, Romijn E, et al. [Cognitive behavioral therapy in combination with pharmacotherapy for adults with ADHD]. Tijdschr Psychiatr 2021; 63:550.</a></li><li><a class="nounderline abstract_t">Corbisiero S, Bitto H, Newark P, et al. A Comparison of Cognitive-Behavioral Therapy and Pharmacotherapy vs. Pharmacotherapy Alone in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)-A Randomized Controlled Trial. Front Psychiatry 2018; 9:571.</a></li><li><a class="nounderline abstract_t">Wilens TE, Morrison NR, Prince J. An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adults. Expert Rev Neurother 2011; 11:1443.</a></li><li><a class="nounderline abstract_t">Heal DJ, Smith SL, Gosden J, Nutt DJ. Amphetamine, past and present--a pharmacological and clinical perspective. J Psychopharmacol 2013; 27:479.</a></li><li><a class="nounderline abstract_t">Daughton JM, Kratochvil CJ. Review of ADHD pharmacotherapies: advantages, disadvantages, and clinical pearls. J Am Acad Child Adolesc Psychiatry 2009; 48:240.</a></li><li><a class="nounderline abstract_t">Subcommittee on Attention-Deficit/Hyperactivity Disorder, Steering Committee on Quality Improvement and Management, Wolraich M, et al. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 2011; 128:1007.</a></li><li><a class="nounderline abstract_t">Pliszka S, AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007; 46:894.</a></li><li><a class="nounderline abstract_t">Cutler AJ, Childress AC, Pardo A, et al. Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study to Evaluate the Efficacy and Safety of Amphetamine Extended-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder. J Clin Psychiatry 2022; 83.</a></li><li><a class="nounderline abstract_t">Rösler M, Fischer R, Ammer R, et al. A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder. Eur Arch Psychiatry Clin Neurosci 2009; 259:120.</a></li><li><a class="nounderline abstract_t">Wender PH, Reimherr FW, Marchant BK, et al. A one year trial of methylphenidate in the treatment of ADHD. J Atten Disord 2011; 15:36.</a></li><li><a class="nounderline abstract_t">Bukstein OG. Therapeutic challenges of attention-deficit hyperactivity disorder with substance use disorders. Expert Rev Neurother 2006; 6:541.</a></li><li><a class="nounderline abstract_t">Jasinski DR, Krishnan S. Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers. J Psychopharmacol 2009; 23:410.</a></li><li><a class="nounderline abstract_t">López FA, Leroux JR. Long-acting stimulants for treatment of attention-deficit/hyperactivity disorder: a focus on extended-release formulations and the prodrug lisdexamfetamine dimesylate to address continuing clinical challenges. Atten Defic Hyperact Disord 2013; 5:249.</a></li><li><a class="nounderline abstract_t">Schelleman H, Bilker WB, Kimmel SE, et al. Methylphenidate and risk of serious cardiovascular events in adults. Am J Psychiatry 2012; 169:178.</a></li><li><a class="nounderline abstract_t">Weisler RH, Biederman J, Spencer TJ, et al. Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial. CNS Spectr 2006; 11:625.</a></li><li><a class="nounderline abstract_t">Cândido RCF, Menezes de Padua CA, Golder S, Junqueira DR. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev 2021; 1:CD013011.</a></li><li><a class="nounderline abstract_t">Boesen K, Paludan-Müller AS, Gøtzsche PC, Jørgensen KJ. Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev 2022; 2:CD012857.</a></li><li><a class="nounderline abstract_t">Volkow ND, Swanson JM. Clinical practice: Adult attention deficit-hyperactivity disorder. N Engl J Med 2013; 369:1935.</a></li><li><a class="nounderline abstract_t">Shaw M, Hodgkins P, Caci H, et al. A systematic review and analysis of long-term outcomes in attention deficit hyperactivity disorder: effects of treatment and non-treatment. BMC Med 2012; 10:99.</a></li><li><a class="nounderline abstract_t">Barkley RA, Cox D. A review of driving risks and impairments associated with attention-deficit/hyperactivity disorder and the effects of stimulant medication on driving performance. J Safety Res 2007; 38:113.</a></li><li><a class="nounderline abstract_t">Jerome L, Habinski L, Segal A. Attention-deficit/hyperactivity disorder (ADHD) and driving risk: a review of the literature and a methodological critique. Curr Psychiatry Rep 2006; 8:416.</a></li><li><a class="nounderline abstract_t">Chang Z, Quinn PD, Hur K, et al. Association Between Medication Use for Attention-Deficit/Hyperactivity Disorder and Risk of Motor Vehicle Crashes. JAMA Psychiatry 2017; 74:597.</a></li><li><a class="nounderline abstract_t">Spencer T, Biederman J, Wilens T, et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2005; 57:456.</a></li><li><a class="nounderline abstract_t">Biederman J, Mick E, Surman C, et al. A randomized, 3-phase, 34-week, double-blind, long-term efficacy study of osmotic-release oral system-methylphenidate in adults with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 2010; 30:549.</a></li><li><a class="nounderline abstract_t">Santosh PJ, Sattar S, Canagaratnam M. Efficacy and tolerability of pharmacotherapies for attention-deficit hyperactivity disorder in adults. CNS Drugs 2011; 25:737.</a></li><li><a class="nounderline abstract_t">Castells X, Cunill R, Capellà D. Treatment discontinuation with methylphenidate in adults with attention deficit hyperactivity disorder: a meta-analysis of randomized clinical trials. Eur J Clin Pharmacol 2013; 69:347.</a></li><li><a class="nounderline abstract_t">Bramness JG, Gundersen ØH, Guterstam J, et al. Amphetamine-induced psychosis--a separate diagnostic entity or primary psychosis triggered in the vulnerable? BMC Psychiatry 2012; 12:221.</a></li><li><a class="nounderline abstract_t">Viktorin A, Rydén E, Thase ME, et al. The Risk of Treatment-Emergent Mania With Methylphenidate in Bipolar Disorder. Am J Psychiatry 2017; 174:341.</a></li><li><a class="nounderline abstract_t">Wilens TE, Hammerness PG, Biederman J, et al. Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2005; 66:253.</a></li><li><a class="nounderline abstract_t">Zhang L, Li L, Andell P, et al. Attention-Deficit/Hyperactivity Disorder Medications and Long-Term Risk of Cardiovascular Diseases. JAMA Psychiatry 2023.</a></li><li><a class="nounderline abstract_t">Zhang L, Yao H, Li L, et al. Risk of Cardiovascular Diseases Associated With Medications Used in Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-analysis. JAMA Netw Open 2022; 5:e2243597.</a></li><li><a class="nounderline abstract_t">Habel LA, Cooper WO, Sox CM, et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA 2011; 306:2673.</a></li><li><a class="nounderline abstract_t">Kelly BD, Lundon DJ, McGuinness D, Brady CM. Methylphenidate-induced erections in a prepubertal child. J Pediatr Urol 2013; 9:e1.</a></li><li><a class="nounderline abstract_t">Cakin-Memik N, Yildiz O, Sişmanlar SG, et al. Priapism associated with methylphenidate: a case report. Turk J Pediatr 2010; 52:430.</a></li><li><a class="nounderline abstract_t">Schwartz RH, Rushton HG. Stuttering priapism associated with withdrawal from sustained-release methylphenidate. J Pediatr 2004; 144:675.</a></li><li class="breakAll">U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA warns of rare risk of long-lasting erections in males taking methylphenidate ADHD medications and has approved label changes. www.fda.gov/downloads/Drugs/DrugSafety/UCM378835.pdf (Accessed on December 18, 2013).</li><li><a class="nounderline abstract_t">Humphreys KL, Eng T, Lee SS. Stimulant medication and substance use outcomes: a meta-analysis. JAMA Psychiatry 2013; 70:740.</a></li><li><a class="nounderline abstract_t">Cassidy TA, Varughese S, Russo L, et al. Nonmedical Use and Diversion of ADHD Stimulants Among U.S. Adults Ages 18-49: A National Internet Survey. J Atten Disord 2015; 19:630.</a></li><li><a class="nounderline abstract_t">Cooper RE, Williams E, Seegobin S, et al. Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial. Eur Neuropsychopharmacol 2017; 27:795.</a></li><li><a class="nounderline abstract_t">Clemow DB, Walker DJ. The potential for misuse and abuse of medications in ADHD: a review. Postgrad Med 2014; 126:64.</a></li><li><a class="nounderline abstract_t">Patrick KS, Straughn AB, Minhinnett RR, et al. Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2007; 81:346.</a></li><li><a class="nounderline abstract_t">Markowitz JS, DeVane CL, Boulton DW, et al. Ethylphenidate formation in human subjects after the administration of a single dose of methylphenidate and ethanol. Drug Metab Dispos 2000; 28:620.</a></li><li><a class="nounderline abstract_t">Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 2002; 27:699.</a></li><li><a class="nounderline abstract_t">Upadhyaya HP, Desaiah D, Schuh KJ, et al. A review of the abuse potential assessment of atomoxetine: a nonstimulant medication for attention-deficit/hyperactivity disorder. Psychopharmacology (Berl) 2013; 226:189.</a></li><li><a class="nounderline abstract_t">Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 2003; 53:112.</a></li><li class="breakAll">Strattera (atomoxetine) capsules for oral use. US Food and Drug Administration (FDA) approved product information. Revised January, 2022, US National Library of Medicine. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021411s050lbl.pdf (Accessed on January 11, 2022).</li><li><a class="nounderline abstract_t">Adler LA, Spencer T, Brown TE, et al. Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial. J Clin Psychopharmacol 2009; 29:44.</a></li><li><a class="nounderline abstract_t">Cunill R, Castells X, Tobias A, Capellà D. Atomoxetine for attention deficit hyperactivity disorder in the adulthood: a meta-analysis and meta-regression. Pharmacoepidemiol Drug Saf 2013; 22:961.</a></li><li><a class="nounderline abstract_t">Asherson P, Bushe C, Saylor K, et al. Efficacy of atomoxetine in adults with attention deficit hyperactivity disorder: an integrated analysis of the complete database of multicenter placebo-controlled trials. J Psychopharmacol 2014; 28:837.</a></li><li><a class="nounderline abstract_t">Durell TM, Adler LA, Williams DW, et al. Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: a randomized, double-blind, placebo-controlled clinical trial. J Clin Psychopharmacol 2013; 33:45.</a></li><li><a class="nounderline abstract_t">Adler LA, Spencer TJ, Williams DW, et al. Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study. J Atten Disord 2008; 12:248.</a></li><li class="breakAll">QELBREE (viloxazine extended-release capsules), for oral use. US Food and Drug Administration. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211964s003lbl.pdf (Accessed on October 28, 2022).</li><li><a class="nounderline abstract_t">Raible H, D'Souza MS. Extended-Release Viloxazine for the Treatment of Attention-Deficit Hyperactivity Disorder in School-Age Children and Adolescents. Ann Pharmacother 2023; 57:1436.</a></li><li><a class="nounderline abstract_t">Price MZ, Price RL. Extended-Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder. CNS Drugs 2023; 37:655.</a></li><li><a class="nounderline abstract_t">Maneeton N, Maneeton B, Srisurapanont M, Martin SD. Bupropion for adults with attention-deficit hyperactivity disorder: meta-analysis of randomized, placebo-controlled trials. Psychiatry Clin Neurosci 2011; 65:611.</a></li><li><a class="nounderline abstract_t">Wilens TE, Haight BR, Horrigan JP, et al. Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study. Biol Psychiatry 2005; 57:793.</a></li><li><a class="nounderline abstract_t">Moriyama TS, Polanczyk GV, Terzi FS, et al. Psychopharmacology and psychotherapy for the treatment of adults with ADHD-a systematic review of available meta-analyses. CNS Spectr 2013; 18:296.</a></li><li class="breakAll">Clayton AH, Gillespie EH. Bupropion. In: The American Psychiatric Publishing Textbook of Psychopharmacology, 4th ed, Schatzberg AF, Nemeroff CB (Eds), American Psychiatric Publishing, Inc., Washington, DC 2009. p.415.</li><li><a class="nounderline abstract_t">Wilens TE, Biederman J, Prince J, et al. Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder. Am J Psychiatry 1996; 153:1147.</a></li><li><a class="nounderline abstract_t">Barrett SP, Pihl RO. Oral methylphenidate-alcohol co-abuse. J Clin Psychopharmacol 2002; 22:633.</a></li><li><a class="nounderline abstract_t">Levin FR, Mariani JJ, Specker S, et al. Extended-Release Mixed Amphetamine Salts vs Placebo for Comorbid Adult Attention-Deficit/Hyperactivity Disorder and Cocaine Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry 2015; 72:593.</a></li><li><a class="nounderline abstract_t">Winhusen TM, Somoza EC, Brigham GS, et al. Impact of attention-deficit/hyperactivity disorder (ADHD) treatment on smoking cessation intervention in ADHD smokers: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2010; 71:1680.</a></li><li><a class="nounderline abstract_t">Levin FR, Evans SM, Brooks DJ, Garawi F. Treatment of cocaine dependent treatment seekers with adult ADHD: double-blind comparison of methylphenidate and placebo. Drug Alcohol Depend 2007; 87:20.</a></li><li><a class="nounderline abstract_t">Levin FR, Evans SM, Brooks DJ, et al. Treatment of methadone-maintained patients with adult ADHD: double-blind comparison of methylphenidate, bupropion and placebo. Drug Alcohol Depend 2006; 81:137.</a></li><li><a class="nounderline abstract_t">Konstenius M, Jayaram-Lindström N, Beck O, Franck J. Sustained release methylphenidate for the treatment of ADHD in amphetamine abusers: a pilot study. Drug Alcohol Depend 2010; 108:130.</a></li><li><a class="nounderline abstract_t">Wilens TE, Adler LA, Weiss MD, et al. Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders. Drug Alcohol Depend 2008; 96:145.</a></li><li><a class="nounderline abstract_t">Adler LA, Guida F, Irons S, Shaw DM. Open label pilot study of atomoxetine in adults with ADHD and substance use disorder. J Dual Diagn 2010; 6:196.</a></li><li><a class="nounderline abstract_t">Kapczinski F, Lima MS, Souza JS, Schmitt R. Antidepressants for generalized anxiety disorder. Cochrane Database Syst Rev 2003; :CD003592.</a></li><li><a class="nounderline abstract_t">Jhanda S, Malhotra S, Grover S. Relationship between bipolar disorder and attention deficit hyperkinetic disorder: An exploratory study. Asian J Psychiatr 2018; 35:101.</a></li><li><a class="nounderline abstract_t">Huybrechts KF, Bröms G, Christensen LB, et al. Association Between Methylphenidate and Amphetamine Use in Pregnancy and Risk of Congenital Malformations: A Cohort Study From the International Pregnancy Safety Study Consortium. JAMA Psychiatry 2018; 75:167.</a></li><li><a class="nounderline abstract_t">Anderson KN, Ailes EC, Danielson M, et al. Attention-Deficit/Hyperactivity Disorder Medication Prescription Claims Among Privately Insured Women Aged 15-44 Years - United States, 2003-2015. MMWR Morb Mortal Wkly Rep 2018; 67:66.</a></li><li><a class="nounderline abstract_t">Ramsay JR. Assessment and monitoring of treatment response in adult ADHD patients: current perspectives. Neuropsychiatr Dis Treat 2017; 13:221.</a></li><li><a class="nounderline abstract_t">Zucker M, Morris MK, Ingram SM, et al. Concordance of self- and informant ratings of adults' current and childhood attention-deficit/hyperactivity disorder symptoms. Psychol Assess 2002; 14:379.</a></li><li class="breakAll">Conners CK, Erhardt D, Sparrow EP. Conners' adult ADHD rating scales: Technical manual, Multi-Health Systems Inc, 1999.</li><li><a class="nounderline abstract_t">Jacobson NS, Truax P. Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol 1991; 59:12.</a></li><li class="breakAll">Barkley RA. Barkley Adult ADHD Rating Scale-IV (BAARS-IV), Guilford Press, 2011.</li><li class="breakAll">Barkley RA. Barkley Deficits in Executive Functioning Scale (BDEFS), Guilford Press, 2011.</li><li class="breakAll">Barkley RA. Barkley Functional Impairment Scale for Adults (BFIS for Adults), Guilford Press, 2011.</li><li><a class="nounderline abstract_t">Brevik EJ, Lundervold AJ, Haavik J, Posserud MB. Validity and accuracy of the Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Self-Report Scale (ASRS) and the Wender Utah Rating Scale (WURS) symptom checklists in discriminating between adults with and without ADHD. Brain Behav 2020; 10:e01605.</a></li><li><a class="nounderline abstract_t">Marchant BK, Reimherr FW, Wender PH, Gift TE. Psychometric properties of the Self-Report Wender-Reimherr Adult Attention Deficit Disorder Scale. Ann Clin Psychiatry 2015; 27:267.</a></li><li><a class="nounderline abstract_t">Weiss MD, McBride NM, Craig S, Jensen P. Conceptual review of measuring functional impairment: findings from the Weiss Functional Impairment Rating Scale. Evid Based Ment Health 2018; 21:155.</a></li><li><a class="nounderline abstract_t">Adler LA. Monitoring adults with ADHD: a focus on executive and behavioral function. J Clin Psychiatry 2010; 71:e18.</a></li><li><a class="nounderline abstract_t">Landgraf JM. Monitoring quality of life in adults with ADHD: reliability and validity of a new measure. J Atten Disord 2007; 11:351.</a></li><li><a class="nounderline abstract_t">Nielsen NP, Wiig EH, Bäck S, Gustafsson J. Processing speed can monitor stimulant-medication effects in adults with attention deficit disorder with hyperactivity. Nord J Psychiatry 2017; 71:296.</a></li><li><a class="nounderline abstract_t">Hays JT, Hurt RD, Rigotti NA, et al. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. a randomized, controlled trial. Ann Intern Med 2001; 135:423.</a></li><li><a class="nounderline abstract_t">Poling J, Oliveto A, Petry N, et al. Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population. Arch Gen Psychiatry 2006; 63:219.</a></li><li><a class="nounderline abstract_t">Shiffman S, Johnston JA, Khayrallah M, et al. The effect of bupropion on nicotine craving and withdrawal. Psychopharmacology (Berl) 2000; 148:33.</a></li><li><a class="nounderline abstract_t">Adler LA, Liebowitz M, Kronenberger W, et al. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder. Depress Anxiety 2009; 26:212.</a></li><li><a class="nounderline abstract_t">Adler LA, Rubin R, Qiao M, et al. Patient characteristics and treatment response to atomoxetine in adults with ADHD versus ADHD comorbid with social anxiety disorder. J ADHD Relat Disord 2010; 1:5.</a></li><li class="breakAll">Donnelly CL, Adler LA, Qiao M, Durell TM. Anxiety response to atomoxetine in patients with attention-deficit/hyperactivity disorder and comorbid anxiety; Poster presented at: 23rd Annual U.S. Psychiatric and Mental Health Congress (USPMHC); November 18, 2010; Orlando, FL.</li><li><a class="nounderline abstract_t">Butterfield ME, Saal J, Young B, Young JL. Supplementary guanfacine hydrochloride as a treatment of attention deficit hyperactivity disorder in adults: A double blind, placebo-controlled study. Psychiatry Res 2016; 236:136.</a></li><li><a class="nounderline abstract_t">Taylor FB, Russo J. Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 2001; 21:223.</a></li><li><a class="nounderline abstract_t">Amiri S, Farhang S, Ghoreishizadeh MA, et al. Double-blind controlled trial of venlafaxine for treatment of adults with attention deficit/hyperactivity disorder. Hum Psychopharmacol 2012; 27:76.</a></li><li><a class="nounderline abstract_t">Weiss M, Hechtman L, Adult ADHD Research Group. A randomized double-blind trial of paroxetine and/or dextroamphetamine and problem-focused therapy for attention-deficit/hyperactivity disorder in adults. J Clin Psychiatry 2006; 67:611.</a></li><li><a class="nounderline abstract_t">Surman CBH, Walsh DM, Horick N, et al. Solriamfetol for Attention-Deficit/Hyperactivity Disorder in Adults: A Double-Blind Placebo-Controlled Pilot Study. J Clin Psychiatry 2023; 84.</a></li><li><a class="nounderline abstract_t">Leffa DT, Grevet EH, Bau CHD, et al. Transcranial Direct Current Stimulation vs Sham for the Treatment of Inattention in Adults With Attention-Deficit/Hyperactivity Disorder: The TUNED Randomized Clinical Trial. JAMA Psychiatry 2022; 79:847.</a></li><li><a class="nounderline abstract_t">Ernst M, Liebenauer LL, Jons PH, et al. Selegiline in adults with attention deficit hyperactivity disorder: clinical efficacy and safety. Psychopharmacol Bull 1996; 32:327.</a></li><li><a class="nounderline abstract_t">Wender PH, Wood DR, Reimherr FW, Ward M. An open trial of pargyline in the treatment of attention deficit disorder, residual type. Psychiatry Res 1983; 9:329.</a></li><li><a class="nounderline abstract_t">Biederman J, Pliszka SR. Modafinil improves symptoms of attention-deficit/hyperactivity disorder across subtypes in children and adolescents. J Pediatr 2008; 152:394.</a></li><li><a class="nounderline abstract_t">Bidwell LC, McClernon FJ, Kollins SH. Cognitive enhancers for the treatment of ADHD. Pharmacol Biochem Behav 2011; 99:262.</a></li><li><a class="nounderline abstract_t">McCartney D, Arkell TR, Irwin C, McGregor IS. Determining the magnitude and duration of acute Δ9-tetrahydrocannabinol (Δ9-THC)-induced driving and cognitive impairment: A systematic and meta-analytic review. Neurosci Biobehav Rev 2021; 126:175.</a></li><li><a class="nounderline abstract_t">Ramaekers JG, Mason NL, Kloft L, Theunissen EL. The why behind the high: determinants of neurocognition during acute cannabis exposure. Nat Rev Neurosci 2021; 22:439.</a></li><li><a class="nounderline abstract_t">Dellazizzo L, Potvin S, Giguère S, Dumais A. Evidence on the acute and residual neurocognitive effects of cannabis use in adolescents and adults: a systematic meta-review of meta-analyses. Addiction 2022; 117:1857.</a></li><li><a class="nounderline abstract_t">Rucklidge JJ, Frampton CM, Gorman B, Boggis A. Vitamin-mineral treatment of attention-deficit hyperactivity disorder in adults: double-blind randomised placebo-controlled trial. Br J Psychiatry 2014; 204:306.</a></li></ol></div><div id="topicVersionRevision">Topic 118534 Version 24.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17470954" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12003449" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The persistence of attention-deficit/hyperactivity disorder into young adulthood as a function of reporting source and definition of disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16420712" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20051220" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19580697" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Pharmacotherapy of adult attention deficit hyperactivity disorder (ADHD): a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22801362" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Pharmacological treatment of adult ADHD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30097390" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20231319" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Efficacy of meta-cognitive therapy for adult ADHD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20736471" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Cognitive behavioral therapy vs relaxation with educational support for medication-treated adults with ADHD and persistent symptoms: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27554190" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The Efficacy of Cognitive Behavioral Therapy for Adults With ADHD: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28413900" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Efficacy of Cognitive Behavioral Therapy With and Without Medication for Adults With ADHD: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26022103" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Cognitive-behavioural therapy in medication-treated adults with attention-deficit/hyperactivity disorder and co-morbid psychopathology: a randomized controlled trial using multi-level analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21787431" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Cognitive behaviour therapy in medication-treated adults with ADHD and persistent symptoms: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33615398" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Efficacy of cognitive behavioural therapy in medicated adults with attention-deficit/hyperactivity disorder in multiple dimensions: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34523707" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : [Cognitive behavioral therapy in combination with pharmacotherapy for adults with ADHD].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30505283" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A Comparison of Cognitive-Behavioral Therapy and Pharmacotherapy vs. Pharmacotherapy Alone in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)-A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21955201" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23539642" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Amphetamine, past and present--a pharmacological and clinical perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19242289" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Review of ADHD pharmacotherapies: advantages, disadvantages, and clinical pearls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22003063" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17581453" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35857716" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study to Evaluate the Efficacy and Safety of Amphetamine Extended-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19165529" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20071637" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : A one year trial of methylphenidate in the treatment of ADHD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16623653" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Therapeutic challenges of attention-deficit hyperactivity disorder with substance use disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18635707" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23564273" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Long-acting stimulants for treatment of attention-deficit/hyperactivity disorder: a focus on extended-release formulations and the prodrug lisdexamfetamine dimesylate to address continuing clinical challenges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22318795" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Methylphenidate and risk of serious cardiovascular events in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16871129" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33460048" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35201607" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24224626" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Clinical practice: Adult attention deficit-hyperactivity disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22947230" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : A systematic review and analysis of long-term outcomes in attention deficit hyperactivity disorder: effects of treatment and non-treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17303170" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : A review of driving risks and impairments associated with attention-deficit/hyperactivity disorder and the effects of stimulant medication on driving performance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16968625" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Attention-deficit/hyperactivity disorder (ADHD) and driving risk: a review of the literature and a methodological critique.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28492937" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Association Between Medication Use for Attention-Deficit/Hyperactivity Disorder and Risk of Motor Vehicle Crashes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15737659" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20814332" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : A randomized, 3-phase, 34-week, double-blind, long-term efficacy study of osmotic-release oral system-methylphenidate in adults with attention-deficit/hyperactivity disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21870887" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Efficacy and tolerability of pharmacotherapies for attention-deficit hyperactivity disorder in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22983311" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Treatment discontinuation with methylphenidate in adults with attention deficit hyperactivity disorder: a meta-analysis of randomized clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23216941" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Amphetamine-induced psychosis--a separate diagnostic entity or primary psychosis triggered in the vulnerable?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27690517" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : The Risk of Treatment-Emergent Mania With Methylphenidate in Bipolar Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15705013" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37991787" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Attention-Deficit/Hyperactivity Disorder Medications and Long-Term Risk of Cardiovascular Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36416824" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Risk of Cardiovascular Diseases Associated With Medications Used in Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22161946" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : ADHD medications and risk of serious cardiovascular events in young and middle-aged adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22552161" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Methylphenidate-induced erections in a prepubertal child.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21043394" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Priapism associated with methylphenidate: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15127013" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Stuttering priapism associated with withdrawal from sustained-release methylphenidate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15127013" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Stuttering priapism associated with withdrawal from sustained-release methylphenidate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23754458" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Stimulant medication and substance use outcomes: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23269194" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Nonmedical Use and Diversion of ADHD Stimulants Among U.S. Adults Ages 18-49: A National Internet Survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28576350" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25295651" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : The potential for misuse and abuse of medications in ADHD: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17339864" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10820132" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Ethylphenidate formation in human subjects after the administration of a single dose of methylphenidate and ethanol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12431845" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23397050" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : A review of the abuse potential assessment of atomoxetine: a nonstimulant medication for attention-deficit/hyperactivity disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12547466" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12547466" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19142107" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23813665" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Atomoxetine for attention deficit hyperactivity disorder in the adulthood: a meta-analysis and meta-regression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25035246" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Efficacy of atomoxetine in adults with attention deficit hyperactivity disorder: an integrated analysis of the complete database of multicenter placebo-controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23277268" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: a randomized, double-blind, placebo-controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18448861" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18448861" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37021356" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Extended-Release Viloxazine for the Treatment of Attention-Deficit Hyperactivity Disorder in School-Age Children and Adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37430151" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Extended-Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22176279" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Bupropion for adults with attention-deficit hyperactivity disorder: meta-analysis of randomized, placebo-controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15820237" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23739183" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Psychopharmacology and psychotherapy for the treatment of adults with ADHD-a systematic review of available meta-analyses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23739183" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Psychopharmacology and psychotherapy for the treatment of adults with ADHD-a systematic review of available meta-analyses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8780417" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12454570" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Oral methylphenidate-alcohol co-abuse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25887096" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Extended-Release Mixed Amphetamine Salts vs Placebo for Comorbid Adult Attention-Deficit/Hyperactivity Disorder and Cocaine Use Disorder: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20492837" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Impact of attention-deficit/hyperactivity disorder (ADHD) treatment on smoking cessation intervention in ADHD smokers: a randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16930863" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Treatment of cocaine dependent treatment seekers with adult ADHD: double-blind comparison of methylphenidate and placebo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16102908" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Treatment of methadone-maintained patients with adult ADHD: double-blind comparison of methylphenidate, bupropion and placebo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20015599" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Sustained release methylphenidate for the treatment of ADHD in amphetamine abusers: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18403134" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Open label pilot study of atomoxetine in adults with ADHD and substance use disorder</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12804478" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Antidepressants for generalized anxiety disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29859501" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Relationship between bipolar disorder and attention deficit hyperkinetic disorder: An exploratory study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29238795" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Association Between Methylphenidate and Amphetamine Use in Pregnancy and Risk of Congenital Malformations: A Cohort Study From the International Pregnancy Safety Study Consortium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29346342" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Attention-Deficit/Hyperactivity Disorder Medication Prescription Claims Among Privately Insured Women Aged 15-44 Years - United States, 2003-2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28184164" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Assessment and monitoring of treatment response in adult ADHD patients: current perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12501563" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Concordance of self- and informant ratings of adults' current and childhood attention-deficit/hyperactivity disorder symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12501563" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Concordance of self- and informant ratings of adults' current and childhood attention-deficit/hyperactivity disorder symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2002127" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Clinical significance: a statistical approach to defining meaningful change in psychotherapy research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2002127" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Clinical significance: a statistical approach to defining meaningful change in psychotherapy research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2002127" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Clinical significance: a statistical approach to defining meaningful change in psychotherapy research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2002127" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Clinical significance: a statistical approach to defining meaningful change in psychotherapy research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32285644" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Validity and accuracy of the Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Self-Report Scale (ASRS) and the Wender Utah Rating Scale (WURS) symptom checklists in discriminating between adults with and without ADHD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26554368" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Psychometric properties of the Self-Report Wender-Reimherr Adult Attention Deficit Disorder Scale.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30314990" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Conceptual review of measuring functional impairment: findings from the Weiss Functional Impairment Rating Scale.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20797374" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Monitoring adults with ADHD: a focus on executive and behavioral function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17494834" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Monitoring quality of life in adults with ADHD: reliability and validity of a new measure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28413936" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Processing speed can monitor stimulant-medication effects in adults with attention deficit disorder with hyperactivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11560455" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. a randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16461866" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10663415" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : The effect of bupropion on nicotine craving and withdrawal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19194995" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Patient characteristics and treatment response to atomoxetine in adults with ADHD versus ADHD comorbid with social anxiety disorder</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Patient characteristics and treatment response to atomoxetine in adults with ADHD versus ADHD comorbid with social anxiety disorder</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26730446" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Supplementary guanfacine hydrochloride as a treatment of attention deficit hyperactivity disorder in adults: A double blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11270920" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22252909" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Double-blind controlled trial of venlafaxine for treatment of adults with attention deficit/hyperactivity disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16669726" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : A randomized double-blind trial of paroxetine and/or dextroamphetamine and problem-focused therapy for attention-deficit/hyperactivity disorder in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37819836" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Solriamfetol for Attention-Deficit/Hyperactivity Disorder in Adults: A Double-Blind Placebo-Controlled Pilot Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35921102" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Transcranial Direct Current Stimulation vs Sham for the Treatment of Inattention in Adults With Attention-Deficit/Hyperactivity Disorder: The TUNED Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8961775" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Selegiline in adults with attention deficit hyperactivity disorder: clinical efficacy and safety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6359210" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : An open trial of pargyline in the treatment of attention deficit disorder, residual type.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18280848" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Modafinil improves symptoms of attention-deficit/hyperactivity disorder across subtypes in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21596055" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Cognitive enhancers for the treatment of ADHD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33497784" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Determining the magnitude and duration of acuteΔ9-tetrahydrocannabinol (Δ9-THC)-induced driving and cognitive impairment: A systematic and meta-analytic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34045693" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : The why behind the high: determinants of neurocognition during acute cannabis exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35048456" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Evidence on the acute and residual neurocognitive effects of cannabis use in adolescents and adults: a systematic meta-review of meta-analyses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24482441" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Vitamin-mineral treatment of attention-deficit hyperactivity disorder in adults: double-blind randomised placebo-controlled trial.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
